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ABSTRACT
Polybrominated diphenyl ethers (PBDEs) are flame retardant chemicals of toxicological
concern present in humans, wildlife, and the environment. Deca-BDE is the highest
production product due to historical use patterns and recent regulatory limitations on the
other two commercial formulations (Penta-BDE and Octa-BDE) in the U.S and Europe.
The EU banned Deca-BDE starting July 1, 2008. However, it remains in usage in North
America and elsewhere in the world. BDE-209 is the dominant congener in all DecaBDE commercial products. BDE-209 has been reported to under go metabolic
debromination to lesser brominated and more toxic and bioaccumulative congeners.
However, insufficient data are available on this process. It has also been observed that
congener profiles and BDE-209 levels in terrestrial organisms differ from most aquatic
species, indicating accumulation or metabolic dissimilarity. The goal of this in ovo study
is to determine the biotransformation and tissue distribution of BDE-209 after injection
into the yolk-sac of embryonic chickens. An emulsion formulation was employed to
better distribute the hydrophobic BDE-209 within the eggs in an attempt to better mimic
“natural” exposure of embryos. Acute mortality from BDE-209 yolk injection was
observed. An LD50 value of 44 pg/egg (740 ng/g ww) was determined for embryonic
chickens in this study. Concentrations of BDE-209 and possible metabolic degradates
were determined in five compartments of the embryos (yolk, brain, liver, heart and
remaining carcass). The results indicated that some BDE-209 was mobilized from the
yolk, into the carcass, liver, brain, and heart tissues of the developing chicken embryo
prior to pipping. However, 80% of the dose was detected as BDE-209 in the yolk sac.
Additional BDE-209 would likely have been assimilated following hatching and
resorption of the remaining yolk. Nona-BDEs were detected in all of the liver and yolk
samples from BDE-209 exposed eggs. The congener profiles of the different tissues did
not indicate that significant metabolic debromination of BDE-209 occurred within the
developing embryos.

Toxicology of Decabromodiphenyl Ether in Avian Embryos:
Disposition of the Flame Retardant BDE-209 in Yolk-injected
Chicken Embryos {Gallus gallus)

INTRODUCTION
Polybrominated diphenyl ethers (PBDEs) are flame retardant chemicals present in
many industrial and household products. PBDEs have been widely used in
thermoplastics, polyurethane foam and in textile coatings (Watanabe and Sakai 2003,
Hale et al. 2003, Law et al. 2006). The chemical structures of PBDEs are reminiscent of
polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs) (Figure LI).
There are a total of 209 individual PBDE congeners possible, as is the case for PCBs and
PBBs, but a limited number are abundant in the commercial mixtures (LaGuardia et al.
2006). The ether linkage between the two phenyl rings in PBDEs, and the presence of
bromines versus chlorines, results in these molecules bearing a closer resemblance to
natural hormone molecules such as iodine-containing thyroxine than the PCBs (Figure
1.2).

Figure LI: PCB versus PBDE

The top m olecule is a polychlorinated biphenyl (PCB) congener; specifically 2 .2 ’,4 .4 ’-tetrachlorobiphenyl
(PC B -47) . The bottom image is the molecular structure o f the polybrominated biphenyl ether (PBDE)
congener (B D E -100).
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Figure 1.2: Thyroxine, T4

c —c

HO

NH
3

OH

S', 3, 5-tetraiodothyronine
thyroxine, T4

Three PBDE commercial mixtures have been in wide commercial use since the
1970s. These products vary in regards to the degree of bromination of their constituent
congeners. Penta-BDE is the least brominated mixture. Its dominant constituents exhibit
from three to six bromines. Octa-BDE contains components that average eight bromine
substitutions, but major congeners exhibit six to nine substitutions. Deca-BDE consists
of about 97% of the fully brominated BDE-209 congener (Figure 1.3).
Figure 1.3: Decabromodiphenyl ether, BDE-209
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The commercial PBDE mixtures are used in different polymer products. The bulk
of Penta-BDE has been employed as an additive in polyurethane foams, common in
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furniture. It appears that Penta-BDE was also used to a limited extent in some circuit
boards until the mid 1990s. Octa-BDE was a more modest use product, mostly as a flame
retardant additive in acrylonitrile-butadiene-styrene (ABS). ABS is a high-impact plastic
used in office electronics, automobiles and kitchen appliances. (Hale et al. 2003,
Watanabe and Sakai 2003)
In 2001, Deca-BDE constituted 83% of total global PBDE use (Hale et. al 2003),
primarily as an additive to high-impact polystyrene1. This plastic is commonly used in
the housings of various electronic devices such as televisions, computers, and related
products. Deca-BDE is also used in latex back-coatings for textiles. Polymer products
can contain up to 30% Deca -BD E by weight. With the cessation of the U.S. production
of Penta-BDE and Octa-BDE in December 2004, Deca-BDE remained as the sole
commercial PBDE product on the North American market.
Deca-BDE is listed as a toxic, high production volume chemical by the US EPA.
As such, it is subject to annual release reporting by US industries using this chemical.
The Toxic Release Inventory Program (TRI) maintains a database on chemical release
documentation going back to 1988. The TRI was originally created under Section 313 of
the Emergency Planning and Community Right to Know Act (EPCRA). The Pollution
Prevention Act of 1990 expanded TRI to pursue data on source reduction as well as
release information. These data are available on-line at the EPA website.

Following

the methods from Hale et al. (2006) a brief analysis of these data was run to update the
dataset of Deca-BDE releases to the environment over the last two decades. The data
from the TRI are accumulated on a voluntary basis, therefore some considerations of the

1 http://www.bsef.com /uploads/library/BSEF_factsheet_Deca-BDE_l 60108.pdf
2 http://www.epa.gov/TRI/
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data quality can not be assured. For more information on this matter the EPA has
released a guidance Document entitled “The Toxics Release Inventory (TRI) and Factors
to Consider When Using TRI Data.”
Figure 1.4: Deca-BDE waste and release figures from the EPA Toxic Release
Inventory
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The global demand for Deca-BDE in 1999 was 54,800 metric tons. (Watanabe
and Sakai, 2003) The American market represented 44% of total global demand, the
Asian 42%, and the European consumption only 14%. Total DecaBDE in US waste for
1999 was 1185 metric tons or 2% of the global demand. Law et al. 2006 reported the
estimated annual production of Deca-BDE to be 30,000 metric tones worldwide.
Hale et al (2009) examined temporal trends of PBDE concentrations in Chicago
biosolids (stabilized sewage sludge) from the 1970s to 2008. The sludge samples showed
a parabolic trend for the Penta-BDE product over time, with peak concentrations around
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the year 2002 and then a decrease (Hale et al. 2009.) This finding is consistent with the
end of Penta-BDE production in 2004. The Deca-BDE concentrations in the Chicago
sewage sludge increased over time. Continued release overtime and high persistence
would support such a trend. Gerecke et al. (2006) found BDE209 to have a half-life of
700 days in anaerobic sewage sludge.

1.1: PBDE Timeline
1970s Manufacturing of PBDEs begins. (Hale et al. 2006)

1981

PBDEs first detected in a river downstream from a textile plant in Stockholm.

2004

The European Union (EU) bans the Penta-BDE and Octa-BDE formulations.
(Kierkegaard et al. 2009)

2004

U.S. PBDE manufacturers, Abermarle Chemical and Great Lakes Chemical,
enter into an agreement with the U.S. EPA to cease production of the Penta-BDE
and Octa-BDE products.

2005

The EU grants a four-year postponement of the ban on Deca-BDE.

2007 Maine and Washington States ban the use of Deca-BDE in electronics and new
mattresses and other furnishings (Kierkegaard, 2009)
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2008 The EU regulates all uses of Deca-BDE through the Registration Evaluation
Authorization of Chemicals (REACH) Program.3

There are regulatory differences between the U.S. and Europe with regard to
PBDEs.

Most usage of Penta-BDE and Octa-BDE ceased in the EU due to

environmental concerns, well before the formal 2004 ban . In the United States their
usage continued until their sole manufacturer, Great Lakes Chemical Company,
voluntarily entered into an agreement with the U.S. EPA to end production by December
2004. Deca-BDE is now believed to be the only PBDE product remaining on the market
in the US and abroad. But its safety remains a controversial issue. Deca-BDE is an
effective flame retardant and a high production volume chemical, generating significant
profits for its manufacturers.
PBDEs have been identified and quantified in many types of environmental and
human samples and concentrations have risen therein since the 1970s (Hites 2004).
Burdens in US samples tend to be higher than in European ones, most likely due to
earlier regulatory actions taken in Europe..
Deca-BDE is a persistent organic pollutant. The major BFR manufacturers have
historically claimed that Deca-BDE does not bioaccumulate and has extremely low
bioavailability. Levels in aquatic organisms are typically much lower than the less
brominated congeners. However, recent research has reported that BDE -209 was
disproportionately high versus other PBDE congeners in some terrestrial organisms, e.g.
grizzly bears (Christensen et al. 2005), red foxes (Voorspoels, 2007) and selected bird
species (Lindberg et al. 2004, Chen et al. 2007, Potter et al. 2009).

The levels of BDE-

’ http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:131:0007:0012:EN:PDF
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209 in terrestrial organisms may be linked with the proximity of the food web to point
sources of PBDE pollution. For example, (Potter et al. (2009) reported that BDE-209
levels in peregrine falcons (Falco peregrinus) from the Chesapeake Bay region were
significantly correlated with population densities.

1.2: Presence of BDE-209 in Birds and the Environment
The fate and persistence of organic compounds is directly related to their structure
and physical-chemical properties. BDE-209 has an octanol/water partitioning coefficient
(log Kmv) of 8.70. (Waina and Dugani, 2003) This high value equates with the
compound being very hydrophobic. The molecular size of BDE-209 and modest
lipophilicity led many to believe it would not bioaccumulate. Elowever, the literature
shows that BDE-209 is detectable in humans, mammals, birds, soils, plants, sewage
sludge, and indoor dust (Voorspoels et al. 2007, Christensen et al. 2005, Hale at al. 2003,
Law et al. 2008).
In 2008, Law et al. reviewed published data on brominated flame retardants
(BFRs) in the European and Asian environments, particularly the concentrations and
trends of BDE209 in biotic and abiotic media. The increasing trend in Europe appeared to
be a leveling off. While, BDE209 concentrations continued to increase in Asian
environments. The leading theory behind this is that the prevalence of electronics
recycling in Asia results in large releases of BDE209 into the environment. Law et al.
(2008) also highlighted the difficulties in analyzing samples for BDE209, in part due to
its low volatility and thermal instability.

Christensen et al. (2005) analyzed fat tissue of grizzly bears from British
Columbia and reported significant differences in the congener profiles of bears feeding in
a maritime versus a terrestrial environment. The differences in diet were determined
using stable isotope analysis. Enriched 513C values indicated more marine food items in
the diet, while enriched 515N values indicated higher trophic prey items. Total PBDEs
detected were not statistically different between the two groups. However, the congener
profiles between the two were remarkably different. The maritime bears contained a
preponderance of lower brominated congeners, i.e. BDE-47>209>99>100>153. The
profiles of inland bears were dominated by more heavily brominated congeners
209>47>207>208.
Another study examining moss samples (Mariussen et al., 2005) further
demonstrated that BDE-209 is capable of entering the terrestrial food web.
Concentrations of BDE-209 in moss samples from Norway ranged from 0.11 to 1.59
pg/kg dw. BDE209 was the dominant congener therein, 85% of the total PBDEs.
Sellstrom et al. (2005) examined uptake of PBDEs by earthworms from sewage sludgetreated soils and reported that bioaccumulation factors decreased with molecular size. In
2007, Voorspoels et al. analyzed PBDEs in tissues of the terrestrial red fox (Vulpes
vulpes.) and found BDE209 was a dominant congener in the tissue profiles, representing
70% of the total PBDEs.
While limited studies are available, burdens of the more brominated PBDE
congeners have been observed to be remarkably higher in some predatory bird species.
For example, a study of peregrine falcon eggs in Sweden detected BDE-209 in 18 of 21
egg samples. The mean concentration values were 130 ng/g lipid in the southern
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population and 110 ng/g in the northern population (Lindberg et al., 2004). Another
European study (Herzke et al., 2005) examined eggs from six species of Norwegian
predatory birds. The species were evenly split between marine and terrestrial feeding
specialists. Herzke et al. (2005) did not report BDE-209 in any of a total of 62 hatched
eggs. However, BDE-183 was quantifiable only in peregrine falcon eggs and was
consistent with the findings of Lindberg et al. (2004). Furthermore, Herzke et al., 2005
documented species dependent PBDE congener patterns. Jaspers at al. (2006) evaluated
oganohalogen body burdens in seven species of aquatic and terrestrial predatory birds
from Belgium. . In this analysis BDE-209 and BDE-183 were only detected in the
terrestrial birds.
Liang et al. (2008) identified BDE-209 as the dominant PBDE congener in
foraging chicken hens from an electronic waste recycling area in southern China. This
study showed peak BDE-209 levels in muscle tissue of 17,977 ng/g lipid wt. Chen et al.
(2007) detected BDE-209 in birds of prey from northern China. Specifically, BDE-209
was detected in 79.4% of the analyzed samples. Furthermore, it was the dominant
congener in samples from some buzzards, scops owls, and long-eared owls. The highest
liver levels of BDE-209 were detected in common kestrels, with a mean of 2,870 and
maximum of 12,200 ng/g lipid weight. These values are much higher than those
previously reported for BDE-209. The authors postulated that the dominance of the
BDE-209 congener in these samples may be related to the large scale production, usage,
and disposal (recycling of obsolete imported and domestic electronics) of Deca-BDE
containing products in China.
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Luo et al. (2009) examined the presence of PBDEs in free-range domestic fowl
within an electronic-waste recycling site in South China. Male and female chickens
(<Gallus domesticus) and ducks (Anas platyrhynchos domesticus) were examined.
Samples of muscle and liver tissue from 51 birds were analyzed for PBDEs. The BDE209 levels were higher in chicken (14-25 ng/g lipid wt.) than ducks (2.1-3.9 ng/g lipid
wt.). While both species eat grain (9.7 ng/g dry wt.), the chickens also foraged for insects
on land and may have been exposed to additional BDE-209 via consumption of soil and
invertebrate prey.
In the USA, relationships between human population densities and PBDE
congener patterns in wild birds have been identified. Potter et al., (2009) examined
peregrine falcon eggs from the Chesapeake Bay region. BDE-209 levels were found to
be significantly higher in birds nesting in densely populated urban areas. The levels of
the octa and nona BDE congeners in these samples typically exceeded the BDE-209
levels. While the reason for this is not fully understood, the authors postulated this was
due to metabolic debromination of BDE-209 within the birds.

1.3: Toxicology and Pharmacology of PBDEs
The US EPA released a Toxicological Review of BDE-209 in June of 2008. This
document is a comprehensive review of the available data on the toxicology of BDE-209.
However, limited data were available for avian species. Therefore, the scope of this
section includes a discussion of the toxicology of all PBDEs in a wide variety of species.
Only dose-response relationships are discussed.
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Traditional feeding studies that exposed mammals to BDE-209 dissolved in a
solvent carrier show uptake rates of only 0.1-5% (Norris et al., 1975; El Dareer et al.,
1987). In feeding study of rats using radiolabeled 14C Deca-BDE (Norris et al., 1975)
assimilation of the dose was low and complete elimination of the isotope was observed
within two days. In contrast, retention of the Octa-BDE product was up to 40% within
the rat. Norris et al. (1975) established a no observed effect level (NOEL) for Deca-BDE
in rats of 8 mg/kg body weight per day in a 30 day dosing trial. Another study showed an
uptake efficiency of 0.025-0.55% of Deca-BDE via dietary exposure over 14 days (El
Dareer et al., 1987).
To mimic stomach contents and enhance the concentration of Deca-BDE
accumulated, Morck et al. (2003) utilized an emulsion-based delivery vehicle, as is often
used in drug delivery studies. It allows for increased suspension of large organic
molecules in water. This approach may act as a more realistic delivery vehicle for dietary
exposure o f BDE-209 and permit heightened detection of candidate breakdown products.
The emulsion delivery vehicle (Morck et al., 2003) for Deca-BDE resulted in a 10% or
greater absorption o f BDE-209 into the rat.
In a combined gavage and intravenous exposure study, Sandholm et al. (2003)
showed an absorption rate o f 26% in the rat. This study used an emulsion carrier similar
to Morck et al. (2003). A total o f 13 phenolic metabolic breakdown products were
identified. This lends further support to the oxidative mechanism proposed by Morck et
al. (2003).
In a feeding exposure and depuration study, Stapleton et al. (2004) observed no
net accumulation of BDE-209 in juvenile carp (Cyprinus carpio). However, seven
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different compounds believed to be BDE-209 metabolites, were found in the exposed
fish. This study was repeated in rainbow trout by Stapleton et al. (2006). BDE-202 was
identified as the dominant breakdown congener. The uptake of BDE-209 into the fish
was determined to be 3.2% based on the body burden of the hepta- through deca-BDEs.
This evidence shows that determining the bioavailability of Deca-BDE is more complex
than simply determining its body burden, as in some organisms degradation products
such as partially debrominated PBDE congeners may predominate.
In a review of the developmental neurotoxicity of PBDEs (Costa and Giordano,
2007) discussed several dose response relationships including: spontaneous behavior
(hyperactivity and decreased habituation) and disruption in learning and memory. It is
believed that these effects are in large part due to disruption of the thyroxine system;
specifically, by reducing circulating thyroxine (T4). Thyroxine is involved in
metabolism and neural development. There are substantial structural similarities
between T4 and PBDEs. Both share the same basic diphenyl ether structure. Both also
contain halogen substitutions; iodines in the case of T4 and bromines in PBDEs.
Bromine is more closely related in the periodic table to iodine than the chlorines present
on, for example, PCBs. T4 is converted to T3 in the body where thyroid hormone
activity is required, by removal of a meta-substituted iodine atom from the phenyl ring.
(Figure 1.5).
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Figure 1.5: Structure of Thyroid Hormones
S t r u c t u r e s o f th e T h y ro id H o rm o n es
T h y r o x in e (T ^ )

COOH
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(http://www.drharper.ca/new page 12.htm)

Endocrine receptor sites may exhibit cross reactivity .with chemicals that bear
structurally similar to the intended hormone. It is possible to suppress (antagonist) or
trigger (agonist) endocrine responses with synthetic chemicals. Antagonist molecules
have the ability to block hormones or agonist molecules from receptor sites. This results
in an inhibition of chemical signals. Agonist molecules bind with receptor sites and
activate bio-chemical pathways. Molecular affinity constants measure the ratio of two
chemicals bound together in solution versus the free forms of those chemicals in solution.
These constants provide a quantitative tool for comparison when considering a variety of
endocrine disrupting compounds (EDCs). Pathways other than the traditions
agonist/antagonist actions exist. Protein transport can be equally important in delivering
hormones and agonists/antagonists to active sites. The organism is not a static system
and metabolic transformation pathways must also be considered. A more holistic view
of the organism must also account for the probable mechanisms of toxic action for the
given compound. A variety of studies have been conducted over the years to evaluate the
toxicity of PBDEs. Acute toxicity of PBDEs appears low. Toxicity is generally thought
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to be greatest for congeners with four to six bromines and to be mediated by
bioavailability. PBDEs have been shown to disrupt endocrine function, resulting in
neurodevelopmental abnormalities, delayed puberty and reproductive issues (Zhou et al.,
2003; Stoker et al., 2005; Costa and Giordano 2007). The nature of PBDE toxicity is
strikingly similar to that of the structurally-related PBBs and non-coplanar PCBs. Dosedependent relationships between contaminants and toxic effects are paramount within
toxicology and risk assessment science. Toxic compounds that bioaccumulate are
especially important as this increases exposure. The summary of toxicology studies
below focuses on observed dose-response relationships between PBDEs and effects.
In 2001, Zhou et al. examined the impacts of oral administration of Penta-BDE,
Octa-BDE, and Deca-BDE commercial formulations on young female rats. Thyroid
hormone levels and hepatic enzyme activities were measured following four days of
exposure at a variety of dosages ranging from 0.3 mg/kg/day to 300 mg/kg/day.
Thyroxine (T4) levels were depressed in the rats treated with Penta-BDE (DE-71) and
Octa-BDE (DE-79). Significant decreases in T4 were observed with dosages of 10
through 300 mg/kg/day. Thyroxine decreased by 80% in the treatment group with the
highest Penta-BDE dose. Thyroxine levels were 70% lower than control in the group
treated with the highest dose of Octa-BDE. Another important finding of this study was
the dose dependent induction of hepatic phase I (CYP1A) and II (UGPDTglucuronosyltransferase is a type of membrane protein residing within cells in the smooth
endoplasmic reticulum) enzymes in the Penta-BDE and Octa-BDE treatment groups.
Significant increases of hepatic enzymes were observed beginning with 30 mg/kg/day
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dosage of both the Penta-BDE and the Octa-BDE. Deca-BDE did not cause any
significant differences in any of the parameters measured in this study.
In a pubertal assay designed as a Tier 1 test for EDCs, male Wistar rats were
orally exposed for three days to a commercial Penta-BDE mixture (Stoker et al., 2005).
A significant dose-dependent decrease was found in the weights of the ventral prostate
(beginning at 30 mg/kg), seminal vesicle (beginning at 60 mg/kg), and Cowper’s gland
(beginning at 120 mg/kg). This study also showed a delay in the onset of puberty in rat
pups orally dosed with the Penta-BDE mixture at 60 and 120 mg/kg.
A group of researchers from Sweden headed by Henrik Viberg, have conducted
numerous studies evaluating the impact of BDE-209 on mammalian brain development.
Viberg et al. (2003) reported that BDE-209 can pass through the blood brain barrier in
mice. Furthermore, the staggering of the doses throughout the neonatal period allowed
for the identification of the most sensitive development stage for BDE-209 exposure, i.e.
day 3 following birth for the mice. Neurobehavioral effects were only detected in the
mice treated on this day. Additionally, the effects observed in these individuals became
more extreme as the mice aged.
This study design was then repeated in rats (Viberg et al., 2005). Abnormal
behavior was observed in young rats two months after being orally dosed with BDE-99.
This study also showed a dose-dependent decrease in muscarinic cholinergic receptors in
the same rats. The response was statistically significant beginning at the 16 mg/kg body
weight dose. These findings mimic earlier work exposing mice to PCBs (Eriksson et al.,
1991).

This study (Viberg et al., 2005) showed that BDE-99 can create persistent
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neurotoxic effects in mice if exposure occurs during a critical phase of neonatal
development.
Another study was run, mimicking the methods of the previous two, to determine
what the impact of BDE-209 would be on developing mammalian brains (Viberg et al.,
2007) The results of this study supported the earlier findings in mice. In addition, this
study included a nicotine-induced behavior test. The key finding here was that nicotine
exposure led to hyperactivity in control and low dose BDE209 treated mice. However,
the animals exposed to the high dose of BDE-209 (21 mg/kg bw) showed hypoactivity
following nicotine exposure. The implications of this finding are that the cholinergic
system is a target for BDE-209-induced developmental neurotoxicity.
The same research group ran another study examining the impact of BDE-209 on
mammalian brain development (Viberg et al, 2008). This time the brains of the animals
were dissected into various components, including the cortex, the hippocampus, and the
whole brain. The concentrations of three proteins were measured in the tissues seven
days after exposure. There were significant differences between the mean concentrations
of all three proteins in various parts of the brain. The three proteins investigated regulate
different neuronal processes associated with survival, growth, and synaptogenesis.
Building upon this work, a similar study was published in 2009 which investigated the
impacts of BDE-209 on two additional neural proteins. Significant differences in protein
levels were not detected for the two proteins examined (Viberg et al., 2009).
Viberg et a f s 2008 study was criticized by flame retardant industry
representatives (Hardy and Stedeford, 2008). Hardy and Stedeford criticized Viberg’s
use of individual pups from the same litter as an experimental unit in the study discussed
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above. Hardy cites EPA methodologies that require toxicity studies control for the “litter
effect” in mammalian studies. Hardy made a similar criticism of another BDE-209 rat
exposure study by Van der Ven et al. (2008a). Van der Ven et al.’s rebuttal is relevant to
the criticism of the Viberg et al. (2008b) study. Acknowledgement is made that there is a
difference of opinion in the scientific community about the statistical methods that must
be used when dosing pups in the neonatal period. Van der Ven goes on to note that the
litter effect is of paramount importance when the dam is exposed and the pups are
evaluated for effects. However, Viberg et al’s studies did not expose the dam. Instead
male pups were exposed after birth in the neonatal period. In addition, Viberg et al
maintained statistical power by using a minimum of three litters for each treatment group.
So the individual pups were used as experimental units, but they do not ALL come from
the same litter.
Van der Ven et al. (2008) conducted a 28 oral dose toxicity study of Deca-BDE in
Wistar rats. This study replicated the gavage and emulsion method designed by Morck et
al., (2003). The most sensitive effect in males was an increase in weight of the seminal
vesicle, beginning at 0.2 mg/kg bw/day, and increased expression of CYP1A and CYP2B
(0.5-0.7 mg/kg bw/day). In females, decreased activity of P450cl7 (CYP17), a key
enzyme in the androgen synthesis pathway, was observed. The authors postulated that
this result may indicate that Deca-BDE poses a reproductive health hazard.

1.4: Metabolism of BDE-209
In mammals BDE-209 is metabolized through an oxidative pathway to form a
variety of hydroxylated PBDEs (EPA, 2008; Morck et al., 2003; Sandholm et al., 2003).
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It is likely that this is mediated by an induced CYP1A reaction triggered by interaction of
BDE-209 with the Arylhydrocarbon receptor (Ahr). The other possible mechanism for
metabolism of BDE-209 is the reductive debromination of the molecule. For this to
occur one of the bromine atoms is removed and replaced with a hydrogen atom. The
products of this pathway would be lower brominated PBDE congeners; which are known
to be more toxic than BDE-209. These would also be more strongly retained than
hydroxylated PBDEs It appears that the reductive pathway occurs in fish (Stapleton et
al., 2006). In adult birds, this may also be the case (Van den Steen et al., 2007).
Activation of thyroxine (T4->T3) requires the removal of an iodine atom from the
5’ position of a diphenyl ether structure (see Figure 1.6). Chicken embryos show 5’monodeiodinase activity (5’-MA) in both the liver and the brain. Valverde et al. (1993)
reported that deiodination activity ceases in the brain around Day 15 of embryonic
development. Valverde et al. made the observation that 5’-MA peaks at day 18-20 in
liver of chicken embryos.
Figure 1.6: Activation of T4->T3
H2N

Type II 5'-monodeiodinase

In BDE-209, the diphenyl ether structure is fully brominated. Assuming
dehalogenation of BDE-209 is facilitated by 5’-MA, logical degradates would be nonaand octa- PBDE congeners, lacking bromines at the position 5 carbons. These would bde
BDE-207 and BDE-197. See figure 1.7. The argument can also be made that other
deiodinases may be present with the ability to remove halogen atoms from all meta
positions. The thought is that the active site of the enzyme might not be specific only to
position 5, rather only specific to the meta postion of the ether linkage. This would create
preferential formation of nona- and octa-BDEs with unsubstituted 3 and 5 position
carbons. Van der Ven et al. (2008) reported production of BDE-207 in the livers of
Wistar rats exposed to BDE209. The ratio of BDE207 to BDE209 was used to track
biotransformation over their 28 study period.
Figure 1.7: BDE-207 and BDE-197

Br

BDE-207

Debromination of BDE-209 in adult starlings was recently investigated by Van
den Steen et al. (2007), using silastic implants to deliver BDE-209 into the blood stream
of starlings. At the conclusion of that study the BDE-209 concentrations in the tissues of
the control birds were below the limit of quantitation of 5.6 ng/g lw (muscle) and 2.9 ng/g
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lw (liver). In the exposed birds the muscle tissue concentrations of BDE-209 were about
twice that of the liver concentrations (430 ng/g lw and 237 ng/g lw respectively.) They
postulated that the liver possessed greater metabolic activity than muscle, reducing
associated BDE209 burdens. This was supported by the observation that the relative
concentrations of the nona-BDEs were greater in the liver than the muscle tissue. This
study showed that, while adult birds are capable of debrominating BDE-209, the
chemical still accumulated in avian tissues. Eggs have been observed to contain both
BDE-209 and apparent debromination products.

1.5: Egg Exposure
Egg injection bioassays have been developed and tested since the 1960s. A
variety of methods exist to deliver compounds to a developing avian embryo. Many
researchers have explored exposing the outer egg shell to petroleum products and
insecticides. There are two main distinctions between egg injection methodologies.
Namely, those that target the air cell of the embryo (i.e., the space between the eggshell
and the outer membrane of the embryo) and those that target the yolk.
Some of the earliest yolk injection studies were designed to evaluate the efficacy
of this test in determining comparative toxicity of different compounds on avian growth
and development (Walker 1967, McLaughlin et al. 1963). In this sense, the findings of
Walker (1967) findings were definitive on the matter. “Chemicals and mixtures of
various types injected into the yolks of fertile eggs moved and reacted in different ways,
depending upon their densities and individual properties”. Clearly, results of tests with
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different modes of toxicant delivery, and therefore different organismal exposures, should
be treated with caution.
Walker’s findings remain crucial in understanding the dynamics of yolk
injections. Further investigations have been conducted to compare the impact of a given
toxicant when injected into either the yolk or the air cell of a chicken embryo. Henshel et
al., (1997) published a study comparing 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
toxicity in developing chicken embryos by these two injection methods. Findings
showed the embryo was more sensitive to TCDD when injected into the yolk (LD50 =
122 pg/egg) than the aircell (LD50 = 297 pg/egg). Henshel’s findings are the opposite of
Gebhardt and van Logten (1968). Gebhardt and van Logten tested the comparative
toxicity of a dithiocarbamate in yolk versus air cell injections to the chicken embryo.
They reported that for these toxicants, the embryos were more sensitive to the thiram
injected into the aircell (LD50 = 1.1 jog), rather than into the yolk (LD50 = 18 pg). In
order to understand these inconsistencies, Walker’s findings must be revisited. Henshel
provides a compelling discussion of these results within the context of Walker’s findings.
Transfer of contaminants from hens to eggs occurs as a continuous process as the
egg is created within the bird. Over time the mother lays down nutrient layers in the yolk
for the developing embryo to consume throughout the development process. There is an
order and structure to the creation of the ovum. Walker (1967) documented the behavior
of a variety o f chemicals when injected into the yolk of the developing chicken egg.
Using various dyes, Walker (1967) tracked the movement and disposition of various
chemicals in chicken yolks. Oils were found to not mix well at all with the yolks, rather
they rose to the top of the yolk as a “single bubble”. Walker reported low mortality for
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vegetable oil yolk injections but high mortality for other compounds that behaved
similarly; rising as a single bubble when injected to the yolk. This is likely due to the
close proximity of the “bubble” with the blastodisc, which also rises in the yolk and
rotates as the eggs are turned throughout incubation
Henshel’s reasoning illustrates many of the facets of the yolk injection exposure
approach. The nature of the carrier may define the exposure, as much as, if not more than
the nature of the toxicant itself. Henshel calls for the evaluation of results within the
context of the injection site and the impact it may play on both physiological and physical
processes occurring within the egg. Figure 1.8 below is Henshel’s Appendix. It presents
a matrix of the advantages and disadvantages inherent in each of the two methods.

Figure 1.8: Appendix from Henshel et. al. 1997 p 732
Air cell
Yolk
Benefits

1. Able to inject throughout incubation.
2. Applied directly onto embryo. This
is especially useful if the chemical is
readily taken up by the embryo.
3. V ehicle is not as critical as for the
yolk, although it may define the
maximum injection volume

Drawbacks

1. Might inject into albumin, and lose
early embryo exposure. (Albumin is
used by the embryo in the latter half o f
the incubation period.) This w ill also
cause a decreased apparent toxicity for
chem icals that also affect early
embryos.
2. If very small quantity is injected, it is
possible that the embryos may not be
exposed to the substance immediately
because a very small amount o f
substance could m ove around the
embryo rather than across the embryo.
3. Maximum recommended total
injection volum es to avoid vehiclerelated embryo mortality: 50 pi for oilbased; 100 pi for water-based.
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1. A ble to inject a larger amount o f chemical
without causing nonspecific embryo mortality.
2. Oil or emulsion-injected material stays near
the top o f the yolk, readily accessible to the
embryo.
3. Material taken up by the embryo by
“natural” processes during yolk absorption,
and distributed with all nutrients through the
embryo
1. N ot as good for later embryo injections, as
one is more likely to damage the embryos or
the vitelline vasculature and cause potential
hemorrhage or abnormal growth.

2. Oil or emulsion tends to be more
concentrated and is not diluted by entire yolk,
so embryo is exposed to higher concentrations
earlier in incubations than if chemical mixed
w ell with yolk.
3. Some diluents or solvents interact with yolk
(e.g. propylene glycol and formaldehyde), and
therefore are not accessible to the embryo,
producing falsely high medial lethal doses
(LD 50s) and median effective doses (ED 50s).

There are several reasons for selecting the yolk over the air-cell injection method
with regards to Deca-BDE: 1) Carriers commonly used in the air-cell injections of the
Penta- and Octa-BDEs do not solubilize Deca-BDE well 2) While the air-cell is within
the eggshell it is separated from the embryo by a membrane. This means that materials
injected into the air cell must first pass through this before contacting the embryo. By
injecting material directly into the yolk of the egg, the food source for the embryo, the
material is immediately available (See Figure 1.9).
Figure 1.9: Egg Yolk Injection

Y o lk

A ir C e ll

Maternal transfer of nutrients into the egg is done in a structured manner;
nutrients are laid down in layers. Obviously, it is impossible to replicate the exact
internal structure and distribution of a contaminant as transferred from hen to egg,
without conducting a feeding study of the hens. Yolk-injection was chosen for this study
because it allowed the preservation of a closed system within the egg. However, the
author desired to have the distribution of yolk-injected BDE-209 similar to what occurs
from maternal transfer. The findings of Walker (1967) are definitive on the behavior of
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various chemicals when injected into the yolk-sac of chicken eggs. Walker determined
that injection of water soluble compounds mixed well with yolk, while oils tended to
move “en masse” with no sign of mixing. An emulsion formulation was chosen because
of the high water content, 78% (w/w) for the emulsion used in these studies. An
emulsion by definition contains oils. Therefore, it is likely that the yolk-injected
material was not dispersed evenly throughout the entire yolk. It is likely that the
emulsion spread somewhat from the original “bubble”. It is also likely, that some of the
original “bubble” remained cohesive. In this case, the embryos would have experienced
greater exposure as the bubble rotated with the embryo inside the eggs throughout
incubation.

1.6: Purpose
The purpose of this study was to examine the biological partitioning of BDE-209,
the major congener of Deca-BDE, in an avian embryo. In the US, the use of Deca-BDE
is currently unregulated at the federal level, although restrictions on some specific
applications are in place in several states4. Restrictions are also under consideration in
Canada and Deca-BDE has been banned in new products in the EU. It remains in
extensive use around the globe as a flame retardant additive in numerous consumer
products. The EPA TRI indicates substantial Deca-BDE releases directly to the
environment and through wastewater treatment plants. Releases directly from in-use
products also occur, as evidenced by its presence at mg/kg levels in indoor dust.
Numerous studies have detected BDE-209 in the environment, and it is often the most
abundant congener in abiotic media such as sewage sludge, soil and airborne particulates.
4 (http://www.bsef.com/regulation/north-america/deca-bde-3/)
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However, until recently, it was not reported in biota. Rather, the constituent congeners of
Penta-BDE (BDE-47, 99, 100, 154 and 154) were typically reported, especially in aquatic
organisms and on occasion at concentrations in excess of 10 mg/kg (lw). Previous
studies have shown that BDE-209 is environmentally persistent and widely distributed.
Based on its large molecular size, strong sorption to particles and low water and lipid
solubility it was originally believed to pose a minimal environmental hazard. This
supposition was supported by studies of aquatic species, which showed almost no
bioaccumulation. However, substantial burdens of BDE-209 have more recently been
observed in some terrestrial birds. In addition, nona- and octa-brominated congeners,
thought to be derived from BDE-209, have also been reported in raptors and their eggs.
Similar congeners have been observed in fish near large BDE-209 point sources (La
Guardia et al, 2007), as well in laboratory feeding studies (Stapleton et al, 2004). These
indicate that a fuller understanding of routes of exposure is critical to evaluate the true
toxicological ramifications of continued Deca-BDE use. . Much lower BDE-209 levels
have been observed in terrestrial mammals than in raptors. Bird eggs are a widely used
environmental matrix to monitor contaminant levels. The toxicology literature indicates
that BDE-209 is rapidly excreted by some mammals (Norris et al. 1975 and Morck et al.
2003). Van den Steen et al. (2007) was the first to demonstrate debromination of BDE209 in birds in the course of an in-laboratory exposure. There has been limited work to
date examining the toxicological impacts of BDE-209 on developing avian embryos.
This is especially relevant as BDE-209 and less brominated congeners, believed to be
BDE-209 degradates, are known to accumulate in terrestrial birds and their eggs.
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It is uncertain whether these metabolic byproducts are produced in-ovo or are pre
existing in the resources transferred from the hen to the egg. The lower brominated
PBDEs have typically been reported to have higher toxicities and bioaccumulative
potentials than BDE-209. Therefore, if BDE-209 is debrominated in the mother hen and
then transferred to the eggs, there is the potential for enhanced toxicity at the beginning
of embryonic development. If BDE-209 is degraded in the embryo to more toxic
metabolites then toxicity may increase throughout embryonic development. This study is
designed to address the latter question.
Tissue distribution is important to consider as well, as chemicals may interfere
with the function of specific organs or biochemical pathways. For example, numerous
studies (Viberg et al. 2003, 2005, 2007, and 2008 amongst others) have shown that BDE209 is developmentally neurotoxic to mammals during the brain growth spurt on day 3 of
life. This study will assess the disposition and acute toxicity of BDE-209, and possible
partial debromination products, in the developing embryo and various critical organs.
Chickens (Gallus gallus) show high sensitivity to toxicants that bind with the Ahr,
and relatively low sensitivity to toxicants which cause egg-shell thinning such as DDT.
The chicken was chosen as an avian model for this study as it is: readily available, easy to
maintain in the laboratory and is a major food source for humans. Substantial levels of
BDE-209 and assumed degradates have been reported in some terrestrial avian species,
including domestic chickens near point sources of Deca-BDE such as electronic recycling
sites, as well as in feral raptors (Liang et al. 2009). The current prevailing hypothesis is
that BDE-209 (the major component of the Deca-BDE commercial product) is more
prevalent in terrestrial than aquatic organisms. Concentrations of BDE-209 in some
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terrestrial birds (130-2000 ng/g lipid) have been observed to exceed by over an order of
magnitude those reported in mammals (<41 pg/kg lipid) (Lindberg et al., 2004; Chen et
al., 2007; Christensen et al., 2005). This study will examine the distribution of BDE-209
following injection into the yolk-sac of chicken embryos. The egg yolk injection
methodology is also expected to maximize the absorbed concentration of BDE-209,
allowing for an increased likelihood of detecting it and any related debromination
products.
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MATERIALS AND METHODS

M .l: Dosing Formulation
An emulsified formulation of BDE-209 was developed for yolk injection into
chicken eggs. The basis for the formulation came from a study (Morck et al., 2003) run
in mammals where the exposure vehicle was designed to better disperse the dose of this
extremely hydrophobic PBDE and mimic stomach contents. The emulsification agents
used were Lptrol® micro 127 MP and Phospholipone® 90G from BASF Corp. (Florham,
NJ) and Lipoid LLC (Newark, NJ), respectively. Decabromodiphenyl ether (BDE-209)
was ordered from Wellington Labs (Guelph, Ontario, Canada). Preliminary work was
done with commercial preparations of Deca-BDE. However, a highly purified (>98%)
BDE-209 standard was required for this study as a major interest was the potential for
biotransformation to less-brominated congeners. The BDE-209 was first dissolved in a
2:1 v/v toluene and diethyl ether solvent mixture. This required the use of a probe
sonicator (type) for 30 minutes. The BDE-209 solution (volume) was then added to an
emulsion vehicle base composed of a mixture of Lptrol® micro 127 MP and
Phospholipone® 90G in a ratio of 34:16 in water. The remaining water was then added
to the solution drop-wise while mixing. The final step was to evaporate off the solvents
using a purified N 2 stream. A total of five treatments were developed; four different
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doses of BDE-209 and an emulsion vehicle. The nominal concentrations of the doses
were 80 pg/egg, 40 pg/egg, 20 pg/egg, and 5 pg/egg. The highest dose (80 |Lig/egg) was
administered in 100 (al injections. The rest of the doses were administered in 50 pi
injections. Therefore the high dose emulsion with a concentration of 800 |ag/ml of
emulsion, was the same emulsion used in the 80 |ag/egg and 40 |ag/egg treatment groups.
This is discussed in more detail below.

M.2: Dose Verification
Nominal concentrations of the BDE-209 emulsions were verified analytically
following the methods of LaGuardia, 2008. The extraction method was designed by the
author with assistance from Mr. LaGuardia. The high, medium, low and vehicle
treatment emulsions were subjected to liquid/liquid extraction using dichloromethane
(DCM) and quantification by gas chromatography and mass spectrometry (GC/MS) in
the electron capture negative ionization (ECNI) mode. Briefly, one ml of each emulsion
was first diluted with 100 ml of DI H2 O before being subjected to three 5 ml extractions
with DCM in a separatory funnel. Each wash with DCM was shaken for five minutes
before allowing the layers to separate and collection of the organic layer. The organic
layers were collected in an appropriate volumetric flask for dilution into the range of the
calibration curve from 50 ng/ml to 5000 ng/ml. The extract of 1 ml of the high dose
emulsion was diluted with hexane into a 500 ml volumetric flask. An aliquot of that
dilution was then analyzed by GC/MS. The ions of interest 79 and 81 (m/z) were
monitored throughout the whole run and used to integrate and quantify BDE-209. The
ion 486 was used to confirm BDE-209. The expected concentration from this 500-fold
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dilution was 1600 ng BDE-209 per ml. The extract of 1 ml of the medium dose emulsion
was diluted with hexane in a 250 ml volumetric flask. An aliquot of that dilution was
then analyzed by GC/MS. The expected concentration from this 250-fold was also 1600
ng BDE-209 per ml. The extract of 1 ml of the low dose emulsion was diluted with
hexane into a 100 ml volumetric flask. An aliquot of that dilution was then analyzed by
GC/MS. The expected concentration from this 100-fold dilution was 983 ng BDE-209
per ml.
The samples were then spiked with 300 ng of decachlorodiphenyl ether (DCDE;
CAS# 3170-30-2) as an internal standard and analyzed by GC/MS in the NCI mode.
Congener peak areas generated were compared to that of the internal standard added to
the extract. Response factors were determined using authentic PBDE standards from
AccuStandard (New Haven, CT, USA) and Cambridge Isotope Laboratories (Andover,
MA, USA).
Instrumental analysis followed that was described previously by LaGuardia et al.
(2006) and Chen et al. (2008). Final extracts were analyzed by GC (6890N, Agilent
Tech., Palo Alto, CA) with MS detection (JMS-GC Mate II, JEOL, Peabody, MA). Ion
fragments were produced in the ECNI mode using methane (99.99%) as the reagent gas.
Injections (1 pi) were made into the splitless injector equipped with a 1 mm i.d. glass
liner. A 15 m DB-5HT column (J&W Scientific, Agilent Technologies, 0.25 mm ID, 0.1
pm stationary phase thickness) was installed in the GC. Helium was used as the GC
carrier gas at an initial pressure of 50 psi. The injection technique used, “pressure pulse
split-splitless”, shows minimal thermal degradation of BDE-209 (LaGuardia, 2008).
Initial column temperature was 90°C and held for 4 minutes. Temperature was then
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increased to 150°C at 30°C/min, then 10°C/min to 300°C and held for 7 minutes. The
column temperature was then increased to 350°C for 5 minutes as a bake out procedure.

M.3: Eggs and incubations
All egg incubation methods followed those from McKeman et al. (2009). Dr.
McKeman was instrumental in the completion of this work, and all experiments at
Patuxent (PWRC) were run under her scrutiny. Preliminary work with the emulsion
vehicle in chicken embryos was conducted at VIMS (Gloucester Point, VA, USA). All
of the procedures involving animals were approved by the Institutional Care and Use
Committees of the College of William and Mary and PWRC. CBT Farms (Chestertown,
MD, USA) supplied the fertile white leghorn chicken (<Gallus gallus) eggs used in studies
employing viable embryos. All of the eggs were washed in a 40°C 1% Betadine®
solution (Purdue, Wilson, NC, USA) upon arrival. Each egg was then weighed and
labeled with a number 2 graphite pencil. The eggs were then stored in a cooler at 13°C
for up to 3 d. Eggs were allowed to equilibrate to room temperature before placement
into incubators. Eggs were artificially incubated (Kuhl Incubator Company, Flemington,
NJ) in trays that rotated eggs horizontally (180 degrees per hour). Incubators were set at
37.6°C, as is recommended for chicken eggs (Henshel et al., 1997). The relative
humidity within the incubator was originally set at 40%. Egg weights were monitored
every 3 to 4 days throughout incubation. The relative humidity was adjusted so the mean
egg weight loss at the end of incubation was 14 to 16%. Eggs were candled at the time of
weighing to confirm viability. Any unfertilized or dead eggs were removed.
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M.4: Dose Administration
These methods were adapted from Quinn et al. (2008) for species differences
between Japanese quail and chickens. Prior to injection, the blunt end of each egg was
cleaned with an alcohol swab and was penetrated using a drill (Dremel, Racine, WI
USA). Two different injection volumes were used in this study; 50 pL and 100 pL. This
is why the various doses were all delivered on a per egg basis. The volume of the yolkinjected dose and control treatments were kept constant in all trials. The doses were
administered to the developing embryos by injection into the yolk-sac using a Hamilton
syringe with a 22 gauge needle. To determine the proper depth to insert the needle, eggs
were measured lengthwise. The average length was then divided by 2 to determine the
center of the egg. A pipette tip was then measured and placed over the tip of the needle
to act as a stop. This allowed the injection to target the center of the egg every time.
Preliminary work was conducted with water and dye to confirm the location of the
injection within the embryo. Separate syringes and needles were used for the vehicle and
treatment groups to prevent contamination. The hole in the egg was then sealed with
ethylene vinyl acetate adhesive using a hot glue gun. All eggs were kept out of the
incubator for an equivalent 30 minutes. Eggs were then placed in trays and positioned
horizontally into the incubator.

M.5: Monitoring Survival and Sample Collections
The methods followed have been described by McKeman et. al.(2009), except for
a modest change in the sample collection timing. Embryo survival was monitored at 3 to
4 d intervals by candling or with a viability detection instrument (Buddy, Vetronic,
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Torquay, UK). The Buddy instrument detects electrical impulses from both the beating
heart of the embryo and any motor movements occurring within the egg. Embryos that
died during development were removed from the incubator and stored in the freezer for
chemical analysis. The endpoint of this study was the 20th day of incubation, as this is
the last day before pipping and followed the peak in liver enzymatic activity. As the goal
was to evaluate in ovo fate of the BDE-209, it was imperative that the chicks were
sampled before they left the closed system of the egg. On Day 19 or 20 the chicks were
removed from the eggshells, weighed, and examined for evidence of edema and
teratogenicity (e.g. eye, foot or bill deformities). The birds were then sacrificed by
decapitation. The liver, heart, brain and remaining yolk-sac were promptly removed and
weighed.

M.6: Trial 1: Evaluation of emulsion vehicle-induced embryonic mortality, VIMS,
December 2007
A total of 20 eggs from CBT Farms in Chestertown MD were received on
12/4/2007. The eggs were candled. One egg was cracked and therefore discarded. The
eggs were then placed in an incubator and maintained at 37°C. Humidity levels were not
monitored, but water was regularly added every few days to the lower tray of the
incubator. At Day 4 all the eggs were candled again. Six of the 19 eggs were not viable
at Day 4 and were discarded. The remaining 13 eggs were randomly assigned to one of
three treatment groups; uninjected (n = 4), deionized water (DI) water injected (n = 4), or
emulsion vehicle injected (n = 5). Assignment was done randomly by rolling a die, two
numbers were selected for each treatment group. The emulsion injection volume used
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was 100 fiL. Incubation was continued through Day 19. The remaining embryos were
then removed from their shells, sacrificed and necropsies conducted. Tissue weights
were recorded for the yolk, liver, and brain.

M.7: Trial 2: Evaluation of emulsion-induced embryonic mortality, VIMS,
February 2008
A total of 47 eggs from CBT Farms (Chestertown MD) were incubated beginning
on 2/15/2008. The eggs were then placed in an incubator and incubated at 37°C.
Humidity levels were not monitored, but water was regularly added every few days to the
lower tray of the incubator. At Day 4 all the eggs were candled again. Two of the 47
eggs were not viable at Day 4 and were discarded. The remaining 45 eggs were
randomly assigned to one of three treatment groups; uninjected (n = 15), sham-injected (n
= 15), or vehicle injected (n = 15). The “sham” injections mimicked the emulsion vehicle
injections, in that the needle was pushed into the yolk. The only difference between the
“sham” and vehicle emulsions is that no liquid was delivered to the yolk in the sham
injections. Treatment assignment was done by tossing a die. The injection volume used
was 100 pL. At Day 19, the embryos were removed from their shells, sacrificed and
tissue weights determined.

M.8: Trial 3: Testing the effects of a single BDE-209 dose on embryonic mortality,
Patuxent Wildlife Research Center, June 2008
Beginning on June 11, 2008 a trial of 198 eggs was run. Initiation and
termination of the trial was staggered over a three day period. This resulted in three
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replicates of each treatment group. On Day 4 of incubation all the eggs were randomly
assigned to one of three treatment groups. The treatment groups in this trial were
uninjected (n = 26), vehicle injected (n = 80), and BDE-209 injected at 80 pg/egg dose (n
= 79.) The injection volume in this trial was 100 pL. Mortality and moisture weight loss
were monitored throughout the incubation period. At Day 19, the embryos were removed
from their shells, sacrificed and necropsied.

M.9: Trial 4: Testing the effect of multiple doses of BDE-209 on embryonic
mortality, Patuxent Wildlife Research Center, July 2008
Multiple doses of BDE-209 were injected into chicken yolks. The injection
volume for this trial was 50 pL. The high dose was 40 pg/egg or 800 pg/ml of emulsion
(n = 47). The middle dose was 20 pg/egg or 400 ug/ml of emulsion (n = 49). The low
dose was 5 pg/ egg or 100 pg/ml of emulsion (n = 43). A total of 30 eggs were also run
as uninjected controls. Again the initiation and termination of this trial was staggered
over a three day period. This resulted in three replicates of all five treatments. Mortality
and moisture weight loss were monitored throughout the incubation period.
On day 19 the embryos were sacrificed by decapitation. The birds in the middle
dose and vehicle treatment groups were necropsied. Five compartments were examined;
liver, heart, brain, yolk, and remaining carcass. These compartments were all weighed
prior to being collected in solvent-rinsed glass jars for further analysis. The tissues and
the yolks from the individual birds were pooled together. Four birds were pooled per
composite sample. So, one set of the five tissue samples contained the tissue from four
individual birds.
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M.10: Experiment 2: Absorption and distribution of yolk-sac administered BDE209
For the chemical distribution aspect of the study, samples were collected from
only the Middle dose (20pg/egg) and Vehicle treatment groups from Trial 4. The Middle
dose treatment group was selected because of the sample size that survived through to the
end of incubation. Due to the small weight of the tissues collected and the expected low
attendant amounts of analyte present, the samples were pooled. Birds within a treatment
group (n = 32 per group) were selected at random for pooling. Four birds were selected
from each treatment for each pool. In an effort to control the total number of samples and
provide statistical meaning, the number of birds collected from each group was
predetermined to be 32. Each pool of four birds resulted in five pooled samples total,
including: livers, hearts, brains, pooled yolks, and carcasses. The total sample size for
each compartment within each treatment was eight. The birds were necropsied
sequentially and the organs were collected in solvent rinsed glass jars.
All tissue samples were subjected to chemical analysis as described by LaGuardia
et al. (2007) and Hale et al. (2001). The first step was freeze-drying for a period of 48
hours (Dura Top, FTS Systems, Stony Ridge NY). Tissue samples and sodium sulfate
blanks were spiked with a surrogate standard consisting of 1000 ng each of PCB-204 and
BDE-166. Dried samples were extracted using enhanced solvent extraction (Dionex
ASE 200, Sunnyvale CA). Two 5-min. extractions were performed per sample with
DCM at 100°C and 1000 psi. Gravimetric analysis of a 10% subsample of the extract
was conducted to determine DCM soluble lipids. Next, size exclusion chromatography
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(SEC) was performed to remove the large molecular weight biogenic lipids from the
analytes of interest (Envirosep-ABC, 350 x 21.1 mm column; Phenomenex, Torrance,
CA). The final purification step was conducted using a 2 g, silica gel, solid phase
extraction column (Isolute, International Sorbent Technology, UK). The first fraction
was eluted using 3 ml of hexane and discarded. The second fraction (S2), containing the
halogenated compounds of interest, was eluted using 10 ml of a 90:10 v/v hexane/DCM
solvent mixture and retained. A third fraction (S3) composed of an additional 5 ml of the
90:10 hexane/DCM mixture was also eluted and collected. The columns were then eluted
with 9 ml of acetone (S4) to remove any remaining potential analytes of interest. The S2
fractions were reduced to near dryness under purified nitrogen and exchanged to hexane.
These were then spiked with 300 ng of the internal standard DCDE. Instrumental
analysis followed that was described previously for the dose verification portion of this
study.

M .ll: Data Analysis and Mass Balance
A major goal of this study was to determine the fate and behavior of BDE-209 in
the developing chicken embryo. To best accomplish this, a mass balance approach was
applied. The mean concentration values of the different tissue samples were multiplied
by the total tissue weights. The sum of these values should equal the original treatment
dose. If the mass measured is less than the amount dosed then it is likely that not all of
the BDE-209 made it through the analytical process, there was biotransformation of the
BDE-209 into other chemicals or errors exist in the measurement of dosage of tissue
residues. Use of pooled tissue samples will also result in some error.
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It should be noted that the high lipid content of the yolk and carcass tissues may
also create matrix interferences in the MS detector. The extraction and cleanup methods
discussed below were optimized to minimize any matrix induced signal interference.

M.12: QA/QC and Method Development
The samples collected from trial four were chemically analyzed for BDE-209 and
potential PBDE-debromination products. Originally all 80 samples (5 tissues with 8
replicates in two treatments groups) were freeze dried in preparation for organic
extraction. Preliminary work was done with the yolk and carcass samples from the
vehicle treatment group, as there was ample sample available from these two tissue
compartments. The method originally tested is described by LaGuardia et al. (2006) and
Hale et al. (2001) and is used routinely on fish samples to quantify PBDEs and other
organic contaminants. Unfortunately, employing this method with the chicken egg
matrix resulted in GC/MS interference issues. In spike recovery studies, the BDE-209
signal in the yolk and carcass matrices was amplified 1.5 to 2 times that of the standards.
This was attributed to excess biogenic material in the final purified extract. Therefore,
modifications to eliminate more of this material from the samples were required.
The solid-phase extraction (SPE) step was the final step for the elimination of co
extracted biogenics. Hence, various column elution options were examined. A weaker
solvent regime would likely elute off less material. Therefore, initially the utility of
100% hexane was examined. BDE-209 was eluted, but required a high volume (15 ml)
o f solvent. Next, a solvent regime of 10% DCM and 90% hexane was next tested. Three
replicates were run. The columns were prepped with 5 ml of 100% hexane. The SPE
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columns were spiked with 1000 ng BDE-209, 480 ng PCB-204, and 480 ng BDE-166.
The first fraction was eluted with 3 ml of hexane and discarded. The second (S2) fraction
consisted of 8 ml of 10% DCM 90% hexane. This was collected, reduced to < 1ml and
spiked with 300 ng DCDE before GC/MS analysis. The third (S2_A) fraction consisted
of an additional 3 ml of 10% DCM. The fourth and fifth fractions (S2_B and S2_C,
respectively), were also 3 ml of 10% DCM. These were also reduced to <lm l and spiked
with 300 ng of DCDE as an internal standard.
Based on the data from the spiked column trial discussed above, a spike recovery
test was run using locally-bought eggs. A dozen large white eggs (nonviable) were
purchased from a commercial grocery chain store (Food Lion, Yorktown, VA, USA).
The yolks were collected from six eggs, pooled, homogenized and freeze dried. For the
other six eggs the yolks and the egg whites were combined, homogenized and freeze
dried. Three replicates of each matrix, as well as three blanks consisting of sodium
sulfate were processed. Each sample was then spiked with 1ml of a composite standard
containing 2000 ng/ml BDE -47, -99, -154,-183, and -209. as well as 820 ng/ml of PCB204 and BDE-166. The samples then underwent extraction on the ASE (Dionex,
Sunnyvale, CA, USA) followed by lipid analysis and size exclusion on the HPLC. Only
56.3% of the original sample material makes it through to the SPE step; due to
mechanism for filling the injection loop. The previously described SPE column study
showed that 8 ml of 10% DCM was insufficient to elute all BDE-209 from the silica gel.
In the spiked matrix study, 10 ml of the 10% DCM was used to elute the S2 fraction.
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Procedural blanks consisting of sodium sulfate were run with every batch of ten
samples. These were spiked with the surrogate standard (BDE-166) and monitored for
possible BDE-209 contamination.

M.13: Statistical Analysis
Contingency Analysis

, Chi-Squared)

The mortality data for each trial were organized into a contingency table; where
the columns represent survival or death and the rows represent the various treatment
groups.
Table M .l: Contingency Table, Observed Values
Observed
Dead Total
x+y
z
w+z
x+y+w+z

Survive
Vehicle
Deca
Total

y

X

w
x+w

y+z . .

The row totals are multiplied by the column totals and divided by the overall total
to calculate expected values.

Table M.2: Contingency Table, Expected Values
Survive

Dead

Total

Vehicle

(x + y) * (x + w)
x+y+w+z

(x + y ) * ( y + z)
x+y+w+z

x+y

Deca

(w + z) * (x + w)
x+y+w+z

(w + z) * (y + z)
x+y+w+z

w+z

Total

x+w

y+z
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x+y+w+z

The final step is to calculate and total the differences between the observed and
expected values using the following formula.

2=y { O - E )2
*

Lu

e

df = (r-l)*(c-l)
r = # of rows, c = # of columns
The null hypothesis for this test is that the treatments (rows) have no impact on
the probability of mortality (columns). The alternative hypothesis is that the rows
(treatments) increase the probability of one of the columns (mortality). The % value and
the degrees of freedom (df) were input into Microsoft Excel to calculate the
corresponding p-value from the probability density function.

Acute Toxicity ~ Calculating the LD50
The Median Lethal Dose (LD50) is a metric often used in toxicology and risk
assessment. The methods used here came directly from the 1995 reference “Quantitative
Methods in Aquatic Ecotoxicology” by Michael C. Newman. In order to accurately
calculate the LD50 for a given compound, and method of exposure, data for multiple
doses are required. Furthermore, the data set must include at least one example of a
partial kill; i.e. mortality other than 0% or 100%. The first step in determining the LD50
for a given set of data is to determine the distribution of the data. This means trying to
determine which model (Normal, Logistic, or Weibull) the data distribution best fits.
Normally distributed data form a bell curve centered on the mean value of a given
parameter in a population. Logistically distributions are similar to normal data, except

42

the bell shows greater kurtosis.. The Weibull distribution is more exponential in
appearance.
In conducting the LD50 analysis, the data distribution plays a key role in
determining the appropriateness or “best fit” of the method used. For example, if the data
are normally distributed, then Probit analysis is most appropriate. If the data are
logistically distributed then Logit analysis is a better tool. Finally, if the data follow a
Wiebull distribution then the Gompertz model is the most appropriate. Determination of
the distribution of the data and selection of the appropriate model can be done by
comparing the Pearson Chi-Square value for each analysis. The Pearson Chi Square
value is provided by the SAS program as a measure of “goodness of fit.” The smaller the
value of the Pearson Chi-Square value the better the fit of the data to the assumed
distribution and corresponding model. The distribution of data points is an important
consideration when fitting models It is widely accepted that the internal areas of the
cumulative density function (CDF) are most accurate. This is one reason why the LD50
is used so often. The accuracy of the models is tested in the external realms of the CDFs
or the tails. Hence, values for LD5 (lethal dose of 5% of the population) and LD99
(lethal dose 99% of the population) are not used as widely. These values can easily be
determined once a model has been fit to the data. This is where the distribution of the
data becomes important. The assumptions made at the beginning of the process have an
impact on the results, especially at the extremes. This is why the Pearson Chi-Squared
value is important in understanding the distribution of the data and hence the selection of
the most accurate model.
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The data from the last two trials were pooled to develop a dose response curve.
Again, the method here follows the 1995 Newman text. These data were then input into
SAS 9 and used to estimate a model of mortality that accounts for the toxicity of the
emulsion itself and not the BDE-209. The data were first fit to a Probit, then a Logit and
finally a Gompertz model. The model with the best fit was identified by the smallest
value of the Pearson Chi-Square Value for the “Goodness of Fit” test. This model was
then used to subtract out the mortality rate of the emulsion carrier. The median lethal
dose of BDE-209 yolk-injected into chicken embryos was then calculated. This is a
toxicological metric often used in risk assessment and policy decision making.
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RESULTS
R.1: Trial 1: Testing the Effect of Egg Injection (Emulsion or DI Water) on
Embryonic Mortality, December 2007
This was the preliminary trial of the yolk injection methodology conducted at
VIMS. Embryos were sacrificed, by design, prior to hatching. A total of 13 eggs were
used in this trial. The weight losses of the eggs during the incubation were slightly greater
than optimal, yet not statistically different, see Appendix A: Figure A.I.
The mortality data are presented in Table R. 1. The null hypothesis tested here
was that yolk injection (DI water or emulsion) would have no effect on embryonic
mortality. The Chi-Square value was equal to 10.19 with a corresponding P<0.05.
There was a significant treatment effect on survival. It is hypothesized that the yolkinjections of DI water caused osmotic shock and embryonic death. The DIH20 treatment
group was excluded from the analysis of the remaining data, as subsequent BDE-209
exposures did not involve DI water as a carrier, Using the remaining data, a Chi-Square
value of 0.99 was calculated with a resulting p-value of 0.32. There was no significant
difference in the mortality between the non-injected and the emulsion injected embryos in
this small trial.
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Table R.1: The Mortality Data for Trial 1
Percent
Survive

Total

Dead

Mortality

Non-inject

4

0

4

0

DIH20-inject

0

4

4

100

Emulsion-

25

inject

4

1

5

Total

8

5

13
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On Day 19 of incubation, the embryos were sacrificed and necropsies were
conducted. None of the embryos had begun to pip through the eggshell. The embryos
were fully feathered. However, the yolk sacs were still external. The summary statistics
for this trial are shown in Table R.2.

Table R.2: Summary Statistics for Trial 1
Crown to
Rump

Body Wt

Yolk Sac Wt

Liver Wt

Brain Wt

E ggW t(g)

Length (in)

w/yolk (g)

(g)

(g)

(g)

58.67(4.14)

3.52(0.21)

44.60(8.12)

16.67(6.01)

0.59(0.14)

0.67(0.12)

Mean

59.07(3.46)

3.57(0.21)

49.57(2.8)

22.12(1.01)

0.55(0.06)

0.66(0.09)

Mean of all

58.84 (3.55)

3.55(0.20)

47.09(6.22)

19.40(4.99)

0.57(0.10)

0.66(.10)

Treatment
Vehicle-lnject
Mean
Non-lnject

Standard deviations reported in ().
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The null hypothesis tested was that there were no differences between the various
measurements in the two treatment groups. One-way ANOVA and follow up Tukey’s
Test were run on the above measurements. No significant differences were detected
between the emulsion-injected and the non-injected groups.

R.2: Trial 2: Testing the effect of yolk-injection on embryonic mortality, (February
2008)
In this trial an automated egg turner was used. A sham injection treatment group
was substituted for the DI water injection treatment to examine the impact of the physical
trauma associated with the injection process. The mortality data for Trial 2 are
summarized in Table R.3. The null hypothesis tested here was that there was no
difference in mortality between eggs injected with the emulsion, sham injected, or non
injected (not-drilled) eggs. The Chi-Squared value calculated for this trial was 1.7 with a
corresponding p value of 0.43. This suggests that there were no significant differences in
mortality between the three different treatments. However, mortalities for all treatments
were high, ranging from 25% to 66%.
The moisture loss data for this trial are presented in Appendix A Figure A.2 . The
moisture weight loss was less than optimal, although again not statistically different.
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Table R.3: Mortality Data for Trial 2
Percent
Survive
Non-inject
Sham-inject

Dead

Total

Mortality

12

3

15

20

9

6

15

40

Emulsion-

40

inject

9

6

15

Total

30

15

45
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R.3: Trial 3: Testing the effects of a single BDE-209 dose on embryonic mortality,
June 2008
In this trial three treatments were examined: an 80 pg/egg BDE-209 dose, vehicle,
and non-injected control. Mass mortality of the BDE-209 injected group occurred within
two days of treatment. The mortality data for this trial are presented in Table R.6. The
Chi-Squared calculated from this table equaled 139.8 (P<0.001). Again the data
suggested an impact of yolk injection on embryonic mortality. By removing the non
injected control group from the analysis, we can determine if there is a statistical
difference between the impact of the emulsion vehicle on embryonic mortality versus the
impact of the BDE-209. Contingency analysis performed on these data yielded a ChiSquare of 103.8 (P<0.001). There was a significant impact on embryonic mortality when
BDE-209 was injected into the yolk, compared to the vehicle emulsion itself. BDE-209
was toxic to embryonic chickens at a dose of 80 pg/egg.
This is the first trial that was run at the PWRC. PWRC performs regular egg
incubation studies and has superior equipment to monitor and control incubator humidity.
The moisture loss data for this trial are presented in Appendix A Figures A.3 through
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A.5. Figure R.6 tracks the moisture weight loss of the BDE-209 injected eggs. Of the
three treatment groups, the BDE-209 injected group deviated the most from the ideal
moisture weight loss function, likely due to the fact that almost all (77 of 79) died
following the injection. Only two embryos survived through to Day 19. The ideal
moisture weight loss function was determined to be 16% of the Day 0 weight at hatch,
day 21. The mean of all eggs within a treatment group on day 0 was multiplied by 0.84
to determine the ideal average weight at hatch, day 21. The two points were then plotted
and a line was drawn to give the ideal moisture weight loss function.

Therefore, an

average of 79 egg weights was used to determine the function shown in Figure R.6. Only
2 eggs were actually tracked through to the completion of the study.
Table R.4: Mortality Data from Trial 3
Percent
Mortality

Survive

Dead

Total

inject

38

1

39

3

Vehicle

66

14

80

17

Deca

2

77

79

98

Total

106

92

198
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Non-

R.4: Trial 4: Testing the effect of multiple doses of BDE-209 on embryonic
mortality, July 2008.
Three BDE-209 doses were injected into chicken yolks. The injection volume
was 50 pL. The high dose was 40 pg/egg or 800 pg/mL, the middle dose 20 pg/egg or
400 pg/mL and the low dose 5 pg/egg or 100 pg/mL. The mortality data from this trial
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are presented in Table R.5. The null hypothesis tested was that the various doses of
BDE-209 injected into the yolks would have no affect on embryonic mortality. The ChiSquared value for this table equaled 34.5 (df = 4) with P<0.001. There was a clear dose
response relationship, as shown in Fig R.7.
Table R.5: Mortality Data from Trial 4
Survive
NonInject
Vehicle
Low
D ose
Mid
D ose
High
D ose
Total

Dead

%
Mortality

Total

30
39

0
4

30
43

0
9.3

42

8

50

16

37

11

49

22

24
172

23
46

47
219
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Figure R.1: Tracking Mortality of 5, 20 or 40 fig/egg doses of BDE-209 in embryonic
chickens versus vehicle control and non-injected treatments
110

100
i _j

J

_i

J

80
70

Day of Incubation
- Mean High Dose

Mean Medium Dose

Mean Low Dose

Significantly different from the V ehicle Control at a o f 0.05

50

Mean Vehicle

Mean Non-inject:

R.4.1 Analysis of Tissue Weights from Trial 4
On Day 20 of Trial 4 the viability of the eggs in all of the treatment groups were
evaluated using the Vetronic Buddy instrument.. All embryos that were alive on the
morning of Day 20 were set to be removed from the eggs and sacrificed by decapitation.
The Middle Dose (n = 41) and the Vehicle (n = 40) treatment groups were necropsied and
various tissue weights were collected. Mortality occurred on Day 20 between the
morning measurements and later sacrifices in both of these treatment groups. In the
Middle Dose treatment group 4 embryos were dead at the time of removal from the egg.
In the Vehicle treatment group, 5 of the embryos were dead at the time of removal from
the eggs. Following death in the egg, the embryonic tissues begin to fill with fluid. The
resulting edema skewed the weight measurements taken from embryos that died before
removal from the egg shell. Therefore the data from these individuals were excluded
from the following analysis of the tissue weights.
Table R.6 presents the tissue weight data from Trial 4. Two-sample T-Tests were
run to determine if BDE-209 had any impact on tissue weights. The null hypotheses were
that there are no differences between the mean tissue weights from the two treatment
groups. At a=5%, none of the treatments were significantly different.
Often data for individual tissues are expressed as ratios relative to the total body
weight instead of as raw values. The calculation to convert the raw value to the tissue
index is shown below.
Tissuelndex =

TissueWeiSht *l00
TotalBody Weight

The transformed tissue data are presented in Table R.7. Two-sample T-Tests
were run to determine if BDE-209 had any impact on tissue weights. The null
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hypotheses were that there are no differences between the mean tissue indices from the
two treatment groups. Again, at a= 5% none of the treatments were significant.
Table R.6: Mean (Standard Deviation) Tissue Weights from Trial 4
TREATMENT
VEHICLE
DECA MID
DOSE

Body wt w/
yolk (g)

Liver
(mg)

Yolk (g)

41 .0 (3 .6 8 )

10.5(2.06)

39.8(3.36)

10.1(1.71)

Brain
(mg)

570
(107)
590
(81.2)

867
(68.6)
877
(62.0)

Muscle
(mg)

Sample
size

178
(28.4)
187
(26.7)

35
37

Table R.7: Mean (Standard Deviation) Tissue Indices from Trial 4
TREATMENT
VEHICLE
DECA MID
DOSE

Liver Index

Brain Index

Heart
Index

Sample size

1.8 7(0.35)

2.84 (0.32)

0.58 (0.10)

35

1.99 (0.24)

2.96 (0.30)

0.63 (0.08)
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R.5: Dose Verification
The high dose was extracted efficiently with recoveries of 85-98%. The middle
dose had lower extraction efficiency with recoveries ranging from 51-79%. The low dose
extractions yielded much lower concentration estimates than expected, i.e. 19, 39 and
52% recovery. The expected concentration of the diluted low dose extractions was lower
(983 ng/mL) than the medium and high doses (1600 ng/mL). As expected, BDE209 was
not detected in the vehicle extractions. These extracts were much more concentrated than
the others, which required substantial dilution to allow BDE-209 quantitation.
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Table R.8: Dose Verification

Sample

BDE209
(ng/ml)

HIGHDOSEREP1
HIGHDOSEREP2
HIGHDOSEREP3

MEAN (SD)

1430
1570
1370

1600
1600
1600

89
98
86

91 (6.4)

1450(100)

MEDDOSEREP1
MEDDOSEREP2
MEDDOSEREP3

MEAN (SD)

Expected
BDE209
% Rec.
(ng/ml)
BDE209

830
1120
1270

1600
1600
1600

52
70
79

67 (14)

1070(223)

LOWDOSEREP1A
LOWDOSEREP2A
LOWDOSEREP3A

186
507
384

MEAN (SD)

359(160)

VEHREP1
VEHREP2
VEHREP3

ND
ND
ND

983
983
983

18
52
39

36 (16)
0
0
0

NA
NA
NA

The BDE-209 standard used in the making of the dosing formulations in this
study was high purity, i.e. >98%. Does not look that high in your below figure However,
the presence of small amounts of nona-BDEs in the BDE-209, and therefore the dosing
solutions, can not be ignored; especially as this study aims to quantify any biological
debromination that may have occurred. Two of the nona-BDEs (-207 and 206) were
identified and quantified to account for the entire mass of the powder dissolved in each
dosing formulation. When the nona-BDEs are taken into account for the medium dose
dilutions the recoveries improve to 70.5%, 85.9%, and 96.7%, respectively. BDE-206
was more abundant than BDE-207. In the medium dose extractions BDE-206
represented on average 15% of the total with BDE-207 contributing 5% of the total
composition.
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Figure R.2: Medium Dose Verification
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Figure R.3: PBDE Congener Profiles for the Middle Dose and Spiking Solution
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M edium D o se

R.6: Calculating the LD50
The Median Lethal Dose (LD50) was determined here by following the methods
presented in the Newman text from 1995.

Figures R.7 through R.9 present the SAS

readouts for the Probit, Logit, and Gompertz Analyses. The Gompertz model had the
lowest Pearson Chi-Square value. Therefore, the data are a better fit to the Weibull
distribution. Figures R.4 through R.6 revealed that the three models all generated
equivalent values for the LD50.
The three models (Probit, Logit, and Gompertz) include a term to account for the
mortality caused by the injection of the vehicle alone. It should be noted here that data
from trials three and four were used to conduct this analysis. Two different injection
volumes were used. These data were only pooled together after careful consideration.
The importance of the LD50 metric in toxicology and risk assessment is that it is widely
used and understood. By pooling the data from two trials, this metric contains more
information on the toxicity of this compound to embryonic birds. However, the trade off
is that the information on the toxicity of the emulsion vehicle is less accurate. The reason
for this is that in trial three 100 pi of vehicle were injected and in trial four only 50 pi of
the vehicle were injected. Therefore the vehicle mortality rate of 16.8% is likely
overestimated for the 50 pi injections and is underestimated for the 100 pi.
All three of the models calculated an LD50 of 44 pg/egg for a 16-day in ovo
exposure. The estimated mortality rate from exposure to the emulsion vehicle ranged
from 16-18%.
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Figure R.4: SAS Readout for Probit Analysis
Probit Analysis (assuming a normal distribution)
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Figure R.5: SAS Readout for Logit Analysis
Logit Model (Assumes a Logistic distribution)
Goodness-of-Fit Tests
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Figure R.6: SAS Readout for Gompertz Analysis
Gompertz Model (Assumes an exponential/Weibull distribution)
Goodness-of-Fit Tests
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Total egg weight changed throughout the course of incubation (-16%) due to
moisture weight loss. The mean initial egg weight was 59.7 g. This yields an LD50
concentration of 740 ng/g egg. If one corrects this value for ideal moisture weight loss of
16% then the value rises to 880 ng/g egg.
In examining the potential toxic impact of these levels of BDE-209 on real world
bird populations, different lethal dose metrics may be examined. Again the accuracy of
these numbers decreases as we move away from the middle (LD50) of the CDF. The
LD10 calculated by the Gompertz model in this study is 21.8 pg/egg. This equates with
365 ng/g egg.
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R.7: BDE-209 Egg Distribution and Biotransformation
R.7.1: Method Development
The solid-phase extraction (SPE) step has been used in the VIMS lab as a viable
step for eliminating co-extracted biogenics from a variety of matrices. However,
preliminary analysis by GC/MS of some egg extracts suggested that excessive biogenic
interferences remained in the purified extract if the solvent regime typically used was
employed. Weaker solvent regimes might elute off less material, so alternative column
elution options were examined. Initially only 100% hexane was used. BDE-209 was
eluted, but required a high volume (15 ml) of solvent. During these trials, it became
apparent that the interaction of bromine with the silica gel column caused the PBDEs to
elute off the column in an unexpected manner. BDE-209, the fully brominated congener,
was expected to be the last of the PBDE congeners to elute from the silica gel column.
However, BDE-209 was actually the first PBDE to elute.

R.7.2: 10% DCM SPE test
A solvent regime of 10% DCM and 90% hexane was next tested. Three replicates
were run. The column was prepped with 5 ml of 100% hexane. The SPE columns were
spiked with 1000 ng BDE209, 480 ng PCB204, and 480 ng BDE166. The first fraction
was eluted with 3 ml of hexane and discarded. The second (S2) fraction consisted of 8
ml of 10% DCM 90% hexane. This was collected, reduced to < 1ml and spiked with 300
ng DCDE as internal standard before GC/MS analysis. The third (S2_A) fraction
consisted of an additional 3 ml of 10% DCM. The fourth and fifth fractions (S2_B and
S2_C, respectively), were also 3 ml of 10% DCM. These were also reduced to <lm l and
spiked with 300 ng of DCDE as an internal standard. In all three replicates BDE-166
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appeared in the S2_A fraction. The appearance of BDE-209 in the S2_C fraction of
replicate 2 was unexpected and may be due to contamination.

Figure R.7: Data from the SPE 10% DCM Test
1200.00

1000.00

R eplicate and Fraction
□ BDE209 (ng)

SP C B 204(ng)____________________ O BDE166 (ng)

R.7.3: PBDE Spike Recovery Study
The results of the egg spiking experiments indicated the recoveries of all the
compounds except BDE-47 and PCB-204 exceeded 80% (Table R.6). Some BDE-47
may still have been retained on the SPE after elution. The overall focus of the project
was on BDE209 and the most likely degradates (nona- and octa- PBDE congeners), so
some loss of low brominated congeners, e.g. tetrabrominated BDE-47, was deemed
acceptable, especially in the face of greater elution of chromatographically co-eluting
biogenic interferences.
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Table R.9: Spike Recovery Test of PBDEs from sodium sulfate (B-FL), Food Lion whole egg (FLWE) and yolk (FLY)
samples.
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R.7.4: QA/QC
Sodium Sulfate (Blanks) samples were run with each pool of 10 samples. The data
from these samples are presented in Table R.10. BDE-209 was not detected in any of these
blank samples.
164rce
LimitofQuantitation —------------------- = 290ng / e
(lg)* (0.5625)
Blank 3 shows a very low recovery of BDE-166. The sample was re-run and the
results were the same. The peak for BDE-166 was definitely present yet the concentration
was too low to quantify.
Table R.10: Sodium Sulfate Spiked Blank Samples
Sample ID
BLANK-2
BLANK-3
BLANK-4
BLANK-5
BLANK-6
BLANK-7
BLANK8
BLANK-2
RERUN
BLANK-3
RERUN
BLANK-5
RERUN
BLANK-8
RERUN

BDE209
(ng/ml)

BDE166
(ng/ml)

% REC

ND
ND
ND
ND
ND
ND
ND

351
<290
505
330
409
485
632

62.4
NA
101.0
66.0
81.8
97.0
126.4

ND

417

74.1

ND

<290

NA

ND

328

58.3

ND

471

83.7

R.7.5: Results from Distribution Study
Tables R.l 1 through R.20 summarize the data from the 80 injected egg samples
collected in the BDE-209 distribution study. These tables are organized by tissue type and
treatment group. The samples are named by tissue type (i.e. B = brain, C = carcass, Y = Yolk,
L = Liver, H = Heart) then treatment (V = Vehicle D = Dosed) and the number of the sample
pool. Each pool number equates with the same four birds, e.g. sample BD4 contains the
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brains of the birds whose carcasses can be found in sample CD4. This allows for both
analysis of tissue mean values and individual pool values.
The quality of the data is evaluated by the percent recovery of the surrogate standard
BDE-166. Any samples where the percent recovery of the surrogate standard was >120% or
<70% or were rerun on the GC/MS. The data from the reruns are reported in the appropriate
table.
Note that the third column in each table entitled “Corrected [BDE-209] (ng/g lw)”
contains the following formula:
CorrectedConcentration[BDE - 209] = (AmountBDE ~ 209) * (0-5625) ^
Upidwt

}g6% Re ^

The constant 0.5625 is the percentage of the ASE sample either not used in lipid
analysis (10% of the sample is consumed in the gravimetric determination of the sample lipid
content) or un-injected in the size exclusion process. In the SEC step the total sample volume
is diluted to 8 ml and the sample is split in two for loading onto the HPLC. The sample
volume charged to the SEC column actually occurs as two injections; one from each 4 ml
sample aliquot. Each injection is only 2.5 ml. So a total of 5 ml of the 8 ml total sample
reaches the column. This is a ratio of 5/8 of the original sample AFTER 10% has been
removed for lipid analysis, hence the 0.5625 factor.
The calibration curve used to quantify BDE-209 (Figure R.8) ranged from 50 ng/ml
BDE-209 to 2000 ng/ml BDE-209. This curve was linear with an R-Squared value of 0.9713.
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^

Figure R.8: BDE-209 Calibration Curve
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R.7.5.1: Brain Samples
BDE-209 was not detected in any of the brain samples from the vehicle treatment
group. (Table R. 12) BDE-209 was detected at high levels in only one of the original brain
samples from the dosed treatment group. (Table R.l 1) This sample (BD8) was rerun (BD8R) and still exhibited high BDE-209 concentrations. BDE-166 recovery was 91%. It is
unlikely that such high levels would be detected in only one of the original dosed brain
samples. It is much more likely that this large BDE-209 signal represents cross
contamination in the laboratory.
After initial analysis the dosed brain samples were reduced in volume and pooled
together from a total o f 7 individual samples (BD8 was not pooled) into two samples. These
composite samples were then analyzed by GC/MS. The results are presented in Table R.l 1A.
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Table R .ll: BDE-209 in Brain Samples from Middle Dose and Vehicle Yolk-injected
_________ ,___________
E g g s_________ _________ _________
Corrected Corrected
Sample [BDE209]
[BDE209] BDE166
ID
(ng/g ww)
% REC
% lipid
(ng/g Iw)
(ng)
BD2
BD3
BD4
BD5
BD6
BD7
BD8
BD8-R*

ND
ND
ND
ND
ND
ND
540
380

ND
ND
ND
ND
ND
ND
9400
6600

BV2
BV3
BV3-R*
BV4
BV5
BV6
BV7
BV8

ND
ND
ND
ND
ND
ND
ND
ND

NA
NA
NA
NA
NA
NA
NA
NA

81
73
79
68
97
76
110
91
83
15
86
66
48
108
80
118
117
104
97
20

453
409
393
338
484
381
551
514
MEAN
STDEV
482
373
271
541
401
592
583
518
MEAN
STDEV

28
30
27
30
26
28
35
35
30
3.4
34
39
39
13
96
29
28
4.8
35
25

* The - R indicates this is a rerun o f the sample. “B ” indicates Brain Sample, “D ” indicates from the middle
dosed group, “V ” indicates from the vehicle control group. The number in the sample ID refers to the specific
samples pool.

Table R.11A: BDE-209 in Composite Brain Samples from BDE-209 -injected Eggs
BDE209
ng/g dw
NEWBRAIN1
NEWBRAIN2

56
ND

BDE166
1920
2150

%Recovery
BDE-166
114
127

*NEW BRAIN1 contains samples BD 1, BD 2, BD 3, and BD4
*N EW BRA fN2 contains sam ples BD 5, BD 6, and BD7.
B D 8 was not pooled due to the high levels o f BD E -209 present.

R.7.5.2: Carcass Samples
Each carcass sample extracted had a dry weight of 1.5 grams. The average lipid
weight of the carcass samples was 0.405 g. The lowest point on the GC/MS calibration curve
was 50 ng/ml. The calculations to determine the limit of quantitation are shown below.
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50 t i p
LimitofQuantitation = ------------= 219«e / glw
(0.405#)* (0.5625)

BDE-209 was not detected in any of the vehicle exposed carcass samples, see Table
R.13. BDE-209 was detected in all dosed carcass samples, see Table R.14. The mean
concentration of BDE-209 in the dosed samples was 574 ng/g lw.

Table R.12: BDE-209 in Carcasses from Middle Dose and Vehicle-injected eggs
Corrected
[BDE209]
(ng/g ww)

Corrected
[BDE209]
(ng/g lw)

CD2
CD3
CD4
CD5
CD6
CD7
CD8

27.0
26.4
18.9
18.7
26.8
25.8
65.7

509.8
529.5
345.8
355.2
534.2
510.6
1235.4

MEAN
STDEV

29.9
16.2

574.4
302.5

CV2
CV3
CV4
CV5
CV6
CV7
CV8

ND
ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND
ND

BDE166
429
459
470
416
585
416
533

MEAN
STDEV
511
418
476
385
589
443
563
MEAN
STDEV

% REC

% lipid

76.3
81.6
83.6
74.0
104.0
74.0
94.8

27.1
25.4
27.9
26.9
25.6
25.8
27.1

84.0
10.6

26.6
0.9

90.8
74.3
95.2
77.0
117.8
88.6
112.6
93.8
16.5

27.5
27.3
26.5
27.5
26.9
23.6
32.6
27.4
2.7

“C” indicates Carcass Sample, “D ” indicates from the middle dosed group, “V ” indicates from the vehicle
control group. The number in the sample ID refers to the specific samples pool.
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R.7.5.3: Liver Samples
The amount of sample available from the pooled livers averaged 0.78 g. The average
lipid weight of the liver samples was 0.39 g. The calculations to determine the limit of
quantitation for these samples are shown below.

LimitofQuantitation

50ng
------------------------= 221 ng I glw
(0.39^) *(0.5625)

BDE-209 was detected in only one of the vehicle-exposed liver samples, see Table
R.16. This sample, LV7, was identified as an outlier and was rerun. LV2 was dropped
during processing and lost. BDE-209 was detected in all dosed liver samples, see Table R.17.
Three of these samples have recoveries below 70% for BDE-166 and were rerun

The mean concentration of BDE-209 in the dosed liver samples was 3640 ng/g lipid weight.
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Table R.13: BDE-209 in Liver from Middle Dose and Vehicle-injected Eggs

Sample
ID
LD2
LD2-R*
LD3
LD3-R*
LD4
LD5
LD5-R*
LD6
LD7
LD8
MEAN
STDEV
LV3
LV4
LV5
LV5-R*
LV6
LV7
LV8

Corrected
[BDE209]
(ng/g ww)
749.3
225.8
743.8
209.1
749.5
971.7
313.6
893.3
679.4
691.6
622.7
273.6
ND
ND
ND
ND
ND
128.000633
ND

Corrected
[BDE209]
(ng/g lw)
5307.8
1599.7
4690.6
1318.8
4810.5
2222.2
717.2
5745.0
5294.0
4658.9
3636.5
1931.1
ND
ND
ND
ND
ND
927.9895732
ND

BDE166
393
283
372
648
449
326
352
533
493
497
MEAN
STDEV
664
409
320
269
566
453
505
MEAN
STDEV

% REC
69.9
50.3
66.1
115.2
89.8
65.2
70.4
106.6
98.6
99.4
83.2
21.5
118.0
81.8
64.0
53.8
113.2
90.6
101.0
88.9
24.1

% lipid
38.8
38.8
43.6
43.6
42.8
120.1
120.1
42.7
35.3
40.8
56.6
33.6
29.0
35.6
47.4
47.4
40.8
37.9
36.4
39.2
6.6

* The - R indicates this is a rerun o f the sample. “L” indicates Liver Sample, “D” indicates from the middle
dosed group, “V" indicates from the vehicle control group. The number in the sample ID refers to the specific
samples pool.

The nona BDEs were detected in all of the dosed liver samples. The data are
presented in Table R.14.
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Table R.14: Nona-BDEs in Dosed Liver samples

SAMPLE
ID
LD1
LD2
LD3
LD4
LD5
LD6
LD7
LD8
Mean
STDEV

Corrected
[BDE207]
(ng/g lw)
129.9
245.2
219.4
443.2
114.7
574.7
674.5
303.1
338.1
206.1

Corrected
[BDE206]
(ng/g lw)
104.1
175.2
225.0
376.2
135.2
529.1
613.4
198.1
294.6
190.3

Corrected
[BDE208]
(ng/g lw)
22.0
108.8
64.9
152.0
37.8
125.6
269.3
86.6
108.4
78.3

“L” indicates Liver Sample, “D” indicates from the middle dosed group, “V ” indicates from the vehicle control
group. The number in the sample ID refers to the specific samples pool.

R.7.5.4: Heart Muscle Samples
The amount of sample available from the pooled heart muscles averaged only 0.1 g.
The average lipid weight of the heart muscle samples was 0.019g. The calculations to
determine the limit of quantitation for these samples are shown below.

50 ng
LimitofQuantitation = --------------------------= 4700n g / glw
(0.019g)* (0.5625)
BDE-209 was not detected in any of the vehicle exposed heart samples, see Table
R. 18. BDE-209 was also not detected in any of the original dosed heart samples, see Table
R.19. The final pre-GC injection volume of these samples was 1 ml. The dosed heart samples
were blown down and pooled together from 8 original samples into 2 new samples and rerun.
The calculations for the new limit of quantitation are shown below.
50 m*
LimitofQuantitation = ----------------------------- -1700ng!glw
(0.019g * 4) * (0.5625)
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Table R.15: BDE-209 in Heart from Middle Dose and Vehicle-in jected Eggs
Sample
ID
MD2
MD3
MD3-R*
MD4
MD5
MD5-R*
MD6
MD7
MD8
MD8-R*

Corrected
[BDE209]
(ng/g ww)
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

Corrected
[BDE209]
(ng/g lw)
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

MV2
MV3
MV4
MV5
MV6
MV7
MV8

ND
ND
ND
ND
ND
ND
ND

ND
ND
ND
ND
ND
ND
ND

BDE166
429
393
507
468
277
398
574
453
715
663
MEAN
STDEV
430
812
491
439
522
399
505
MEAN
STDEV

% REC
76.3
69.9
90.1
93.6
55.4
70.8
114.8
90.6
143.0
117.9
92.2
26.5
76.4
144.4
98.2
87.8
104.4
79.8
101.0
98.9
22.7

% lipid
20.0
14.0
14.0
22.0
36.0
36.0
18.0
18.0
18.0
18.0
21.4
7.6
4.0
16.0
13.0
31.0
10.0
11.0
19.0
14.9
8.6

* The - R indicates this is a rerun o f the sample. “M ” indicates Heart Muscle Sample, “D” indicates from the
middle dosed group, “V ” indicates from the vehicle control group. The number in the sample ID refers to the
specific samples pool.

Table R.15A: BDE-209 in Composite Heart Samples from BDE-209 injected Eggs

NEWHEART1
NEWHEART2

BDE209
ng/g dw
245
184

BDE166
1950
1980

%Recovery
BDE-166
116
117.

*NEWHEART1 contains samples MD1, MD2, MD3, and MD4
*NEW HEART2 contains samples MD5, MD6, MD7,and MD8.
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R.7.5.5: Yolk Samples
Each yolk sample had a dry weight of 1.0 g. The average lipid weight of the yolk
samples was 0.4 lg. The calculations to determine the limit of quantitation for these samples
are shown below.

Lower lim itofQuantitation = ------- 200ng
_ g^y
(0.41#) *(0.5625)

/

The highest point on the extended GC/MS calibration curve was 2000 ng/ml. The
calculations to determine the upper limit of quantitation for the curve are shown below.
UpperLimitofQuantitation = ------ -000/7#------- _ g^yQ
(0.41#) * (0.5625)

/ gjw

BDE-209 was not detected in any of the vehicle-injected yolk samples, see Table
R.19. The dosed yolk samples were all run in triplicate, as there was plenty of material
available for analysis. BDE-209 was detected in all dosed yolk samples. The mean
concentration of BDE-209 in the dosed samples was 6000 ng/g lw. Many of the detected
values were above the upper limit of quantitation identified above.
The yolk samples were diluted 5-fold to bring the BDE-209 concentrations within the
range of the calibration curve. These concentrations were found to be reasonable and well
within the expected range given the total dose administered to the embryos. Therefore,
further work with 13C-labeled BDE-209 was not required.
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Table R.16: BDE-209 in Yolk from Vehicle-injected Eggs

Sample ID
YV2
YV3
YV4
YV5
YV6
YV7
YV8

Corrected
[BDE209]
(ng/g ww)
ND
ND
ND
ND
ND
ND
ND

Corrected
[BDE209]
(ng/g lw)
ND
ND
ND
ND
ND
ND
ND

BDE166
(ng/ml)
437
371
496
516
429
536
507
MEAN
STDEV

% REC
77.7
66.0
99.2
103.2
85.8
107.2
101.4
91.5
15.4

% lipid
32.2
38.7
45.8
44.5
42.8
43.6
48.9
42.4
5.4

‘Y” indicates Yolk Sample, “D” indicates from the middle dosed group, “V ” indicates from the vehicle control
group. The number in the sample ID refers to the specific samples pool.

Table R.17 : BDE-209 in Diluted Yolk Samples from BDE-209-injected Eggs

Sample ID
YD1*A5-1
YD2*A5-1
YD3*A5-1
YD4*A5-1
YD5*A5-1
YD6*A5-1
YD7*A5-1
YD8*A5-1
Mean
SD

BDE-209 (ng/g
dw)
2213
3520
3120
3947
3716
4098
4240
3858
3589
656

BDE-209 (ng/g
lw)
5533
8800
7800
9867
9289
10244
10600
9644
8972
1640

% Recovery BDE166
49.07
58.40
61.78
68.44
45.07
42.40
69.51
65.42
58
10.7

*A5-1 Refers to analytical replicate A diluted by a a factor of 5. “Y” indicates Yolk Sample, “D” indicates
from the middle dosed group, “V” indicates from the vehicle control group. The number in the sample ID refers
to the specific samples pool.

Nona BDEs were detected in all of the dosed yolk samples. Figure R.9 presents the
mean values for the three nona-BDEs in the dosed yolk samples.
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Figure R.9: Mean Nona-BDEs in Dosed Yolk Samples
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Two unknown heavily brominated compounds were also detected in YD7 and YD3.
The chromatograms and spectra for these samples are shown below in Figures R.10 through
R.22.
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Figure R.10: Chromatogram of Sample YD7
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The spectra were compared to the spectra from La Guardia’s ECNI BDE Spectra
Library5. The two compounds with retention time 20.52 min. and 22.82 were not identified as
PBDE congeners. They may be potential breakdown products of BDE-209 or contaminants
in the analytical process. From the MS spectra, these two compounds are clearly brominated,
due to the presence of the 79 and 81 m/z and with ion clusters at about 80 m/z intervals
indicative of bromine losses.
The spectrum for Unknown Compound A is shown in Figure R.20. The 722 ion is
indicative of a compound containing seven bromines (12 Carbons, 1 Oxygen, and 7
5 http://www.viins.edu/people/laguardia mi/pubs/LaGuardia Spectra%20Librarv%20% 20ECNI% 20PBDEs.pdf).
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bromines). This is most likely a polybrominated dibenzofuran (PBDF) with eight bromines.
The molecular ion was 800 with M-Br at 720 m/z. Figure R.21 shows the basic structure.
Figure R.11: Mass Spectrum of unknown Compound A with Retention Time of
20.52 min.
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Figure R.12: Dibenzofuran Molecular Structure

9

1

dibenzofuran
The detection of this brominated furan raises questions. Of paramount importance is
the origin of this compound. The dose verification samples were re-checked for this
compound and other fiirans. None were found. The distribution samples were rechecked for
this and other furans and some samples were found to contain this compound. This
compound was only detected in the dosed yolk samples and in none of the other matrices
from the distribution study. More specifically, only three of the dosed yolk samples showed
the presence of this compound (YD3, YD7, and YD8). However, this PBDF was only
detected in all three replicates of YD7. Only one replicate for the samples YD3 and YD8
showed the presence of this compound.
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Figure R.13: Spectrum for Unknown Compound B with Retention Time of 22.82
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The replicates for sample YD7 showed similar patterns.
The molecular ion is 842, the other clusters are 757, 673 and 599.
It has been suggested that this is a diphenyl ether with not chlorine and bromine substitutions
that is an impurity in Deca-BDE. There are no data showing that this compound was present
in ANY of the dosing emulsions. Ion 488 was plotted for the extractions of all the dosing
formulations to confirm whether or not this was an impurity found in the dose itself. None of
the medium dose replicates had a peak for ion 488 at the 22.82 retention time. The original
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BDE-spiking solution used to make the dosing emulsions also does not show the presence of
this compound. None of the Low Dose, High Dose, or Vehicle samples show this compound
either. The yolk vehicle samples also show no sign of this compound. Again the 488 ion was
plotted up for each sample.
This compound was found in all three replicates of every one of eight dosed yolk
samples. The 444 ion was plotted up and all 24 samples had a peak at 22.82 minutes with the
spectra shown in Figure R.13. The liver samples showed an identical pattern. All eight of the
dosed liver samples had a peak at 22.82 with a spectra matching Figure HH. None of the liver
samples in the vehicle treatment showed the presence of this compound.
Examination of the standards used to make the calibration curve revealed the presence
of this doubly halogenated compound. Therefore, the determination was made that the
presence of this compound represents analytical cross contamination. Where this compound
was detected the levels were extremely low; typically below the 1:10 signal to noise ratio
required for quantitation.

R.7.5.6: Mass Balance Calculations
All the samples collected for the tissue distribution evaluation were derived from the
Middle Dose treatment group. This treatment group was selected for analysis due to the
survival rate throughout the experiment. Each egg was injected with 20 pg of BDE-209, so
each embryo theoretically contained 20,000 ng of BDE-209. During collection the embryos
were pooled into groups of four. Each pooled sample contains the select tissue from four
individuals. Therefore, the dose must be summed over four embryos; 80 pg of BDE-209 is to
be accounted for in the five tissue compartments of the embryo. This analysis first examines
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the data from the entire distribution experiment using the mean concentration values from
each of the tissue compartments. Follow-up analysis is done examining the individual sample
pools and can be found in Appendix C.

Figure R.14: Distribution of BDE-209 in Yolk-Injected Chicken Embryos Using Mean
Tissue Concentrations
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The mean total carcass dry weight was 25.8 g.

The mean concentration of BDE-209

detected in the dosed carcass tissue samples was 130 ng/g dw. This gives an average total
amount of BDE-209 in the carcass tissues of 3400 ng, or 4.25 % of the total dose.
The mean total liver dry weight was 0.92 g. All the liver tissue was utilized during
sample processing. The mean concentration of BDE-209 detected in the dosed liver samples
was 1600 ng/g dw. This gives an average total amount of BDE-209 sequestered in the liver of
1470 ng, or about 2% of the total dose.
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The mean total yolk dry weight was 19.33 g.

The mean concentration of BDE-209

detected in the dose yolk samples was 3600 ng/g dw, yielding an average total amount of
BDE-209 in the yolk compartment of 69,000 ng. This represents 87% of the total 80,000 ng
delivered to each sample pool.
BDE-209 was not detected in any of the individual sample pools for the heart and
brain tissues. The individual sample pools were combined and further concentrated. The
pools of these small tissues exhibited nondetectable to low concentrations. The mean total
dry weight of the hearts was 0.16 g. The mean concentration (of the reduced sample size n =
2) was 214 ng/g dw. This equates to less than 1% of the total dose for the sample pool.
The mean total dry weight of the brain tissues was 0.54 g. BDE-209 was only
detected in one (65 ng/g dw) of the two concentrated samples. However, this value is used
due to the fact that the other sample only contained three rather than four of the pooled
samples. This equates to less than 1% of the total dose.
Consideration of the nona-BDEs (BDE-207, 207 and 208) must also be taken into
account. The mean total concentration of all three nona-BDEs in the yolk and liver tissues
were quantified. In the dosed yolk samples, the mean total nona-BDE concentration was 580
ng/g dw. As the total mean yolk dry weight was 19.33 g, this represents a total nona-BDE
contribution of 11,200 ng or 14% of the total administered dose. In the dosed liver samples,
the total mean nona-BDE concentration was 260 ng/g dw. Again, the mean total liver weight
was 0.92 g, yielding a total of 240 ng, or less than 1% of the total dose.
As the mean nona-BDE concentrations were elevated due to the presence of elevated
levels in sample pool 7, a pool by pool mass balance analysis is indicated.
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A one-way ANOVA and follow-up Tukey’s test was run to determine if the congener
composition of the original dose formulation, the yolk and liver compartments were
statistically equivalent. At a= 0.05, the only statistically significant difference was a higher
BDE-206 percentage in the dose than the liver or yolks of the bird.
Figure R.15: PBDE Congener Profile for the Dosed Yolk, Dosed Liver, and
Emulsion Dose

Em ulsion Dose

Statistically significant at a = 0.05.
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DISCUSSION
D.l: Toxicity of BDE-209
Data on toxicity of Deca-BDE to avian species are scarce. The analysis conducted
here used the nominal concentrations of BDE-209 from trials three and four of this study.
The requirements for this type of survival analysis were met; at least one treatment group
resulted in a partial kill of the exposed population and there was a clear dose-response
relationship. In this case, comparison of the Pearson Chi-Square values revealed that the
Gompertz distribution was the best model, with a calculated LD50 value of 44pg/egg (740
ng/g ww).

Selection of the most appropriate, and therefore accurate model, allows for a

more accurate elucidation of the LD5 and LD10 values.
The Median Lethal Dose (LD50) is a basic metric used in risk assessment and
toxicology. It identifies the dose of a given chemical at which half of the exposed study
population dies. As such, it is useful for comparing the relative toxicities of chemicals. The
chemical 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is one of the most toxic compounds in
existence. As such, it is often used as the metric against which other toxins are measured
against. In terms of Toxic Equivalency Factors (TEF) TCDD has the highest possible score
of 1. The LD50 value reported for yolk injection of TCDD to chicken embryos is 122 pg/g
egg (Henshel et al., 1997). This value is about 6000-times smaller than the LD50 value
calculated in this study. Therefore, BDE-209 is about 6000-times less toxic to developing
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chicken embryos than TCDD. This gives BDE-209 a relative potency of 0.000165 when
compared to TCDD.
In birds, there are limited data available on the toxicity of PBDEs. Air-cell injection
of the Penta-BDE mixtures resulted in decreased pipping and hatching success in American
kestrels but not in chickens or mallards (Mckeman et al., 2009). Based on this dose and
absorption rate of the dose from the aircell into the embryo, a Lowest Observed Effect Level
(LOEL) of 1800 ng/g ww was determined. This is higher than the LD50 calculated in this
study by a factor of 2.43.
In rats, a No Observed Effect Level (NOEL) for Deca-BDE of 8 mg/kg body weight
per day in a 30 day dosing trial was determined by Norris et al. (1975). This was a traditional
feeding study where Deca-BDE was added to food using a solvent carrier. The NOEL is a
more sensitive endpoint than the LD50. It is the lowest treatment dose that elicited no
statistically significant effect in a study where a dose-response effect was measured. For this
study the NOEL ranged from 84 to 94 ng/g ww. The reported NOEL values from oral
toxicity studies in mammals ranged from 100 mg/kg (Zhou et al. 2001) to 23,000 mg/kg (EPA
2008), with the majority o f these studies not determining a LOEL (lowest observable effect
level). These NOELs are much higher than the LD50 determined in the present study. The
lack o f studies reporting LD50 value for BDE-209 in mammals indicates that the compound is
not very toxic to mammals in an acute exposure scenario. This is supported by the data
showing the metabolic breakdown and excretion of BDE-209 in mammals. In birds, this
mechanism results in the excretion of both the parent compound (BDE-209) and possible
metabolic products into the egg. This results in a developmental exposure scenario.
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A thorough toxicological review of BDE-209 was released by the US EPA in 2008
(EPA/635/R-07/008F). Minimal attention in this document was paid to acute lethal effects
from BDE-209 exposure. In fact, the document fails to report any LD50 values for
comparison. This is largely due to the fact that BDE-209 is believed to be relatively non
toxic. PBDEs emerged in the market place at a time when more toxic compounds (i.e. PCBs)
were being removed due to toxic concerns. In the four decades of PBDE use, data have
emerged that indicate that these compounds are not benign. Government restrictions are now
in place limiting the use of PBDEs in a manner reminiscent of the treatment of PCBs. While,
PBDEs are generally less toxic than their predecessors, the PCBs, they still behave as
endocrine disrupting compounds (EDCs) in the environment. Therefore, it becomes crucial to
examine the sublethal toxic effects of PBDEs and BDE-209.
Sublethal effects have been well documented for BDE-209 in mammals. The 2008
EPA Document (EPA/635/R-07/008F) presents a thorough review of these studies.
Reproductive and developmental toxicity values are much lower than the subchronic toxicity
values discussed above for mammals. Neurobehavioral effects relating to chlolinergic system
have been reported (Viberg et al. 2007). The LOEL values for these types of effects range
from 6.7 mg/kg (Viberg et al.2007) to 20.1 mg/kg (Viberg et al. 2003) for the single dose
studies. The LOELs from the multi-dose studies range from 6.1 mg/kg/day (Rice et al. 2007)
to 500 mg/kg/day (Tseng et al. 2007). The LOEL for the present study was the middle dose
of 20 (Lig/egg, which equates to 335 ng/g ww to 376 ng/g ww.

These LOELs are an order of

magnitude lower than the lowest values reported in mammals.
In a feeding study of American kestrels exposed to DE-71 and ahexabromocyclododecane (HBCD) (Femie et al., 2009) egg shell thickness declined with
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increasing concentrations of PBDEs and HBCD. This effect was not correlated with levels of
BDE-183 and -209. The potential for metabolic breakdown of these larger congeners to the
more potent BDEs exists in the adult bird. Femie et al. go on to postulate that PBDE and
HBCD related egg shell thinning is already having an observable effect on brood size in
Europe and the decline of the North American kestrel population.
Evaluating this toxicity value within the context of BDE-209 levels detected in bird
eggs is important. The LD50 values from this study equated to concentrations ranging from
740 to 803 ng/g ww . Figure D.l explores published BDE-209 levels in avian eggs. The
levels of BDE-209 in avian eggs from around the world are all an order of magnitude less
than the LD50 of 7000 ng/g lw calculated for this study. Conversion of the NOEL and LOEL
to a lipid weight basis result in a range of 837-1340 ng/g lw (NOEL) and 538-3350 ng/g lw.
In examining the potential toxic impact of these BDE-209 levels on real world bird
populations, different lethal dose metrics may be examined. Again the accuracy of these
numbers decreases as we move away from the middle (LD50) of the CDF. The LD10
calculated by the Gompertz model in this study was 21.8 pg/egg, the LD5 was 16.7 pg/egg.
These values correspond to a range of 3000 to 3500 ng/g lw for the LD10 value and 2650 to
2800 ng/g lw for the LD5 metric.
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Figure D.l: Levels of BDE-209 in wild bird eggs from various locations around the
world

2. Sweden

3. Greenland

4. Michigan U S

1. G a u th ie r et al. (2008) h e rrin g gulls 2. L in d b erg et al. (2004) p eregrine falcon 3. V orkam p et al. (2005)
p ereg rin e falcon 4. C hen et al. (2008) peregrine falcon

The LD10 and LD5 values are still an order of magnitude higher than the BDE-209
levels detected in wild bird eggs. (See Figure D .l) The conclusion of this analysis is that
BDE-209 levels in wild bird populations are lower than the threshold values for acute toxicity.
It must be noted, that as the true mechanism of BDE-209 toxicity is not known in avian
embryos, the potential for chronic effects still exists. Note that uncertainty factors applied are
typically a factor of 10. Also that, in the present study, exposure was terminated before
assimilation of the yolk sac and that the 80% of the BDE-209 remained in the yolk.
Additional work is indicated to examine the distribution of this BDE-209 between waste and
yet unutilized energy reserves and the potential impact of assimilation of the BDE-209
associated with the latter.
In an effort to explore sublethal endpoints in the present study, the embryos from the
middle dose (20 pg/egg) and the Vehicle treatment groups were necropsied and the weights of
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five tissues determined.

Exposure to BDE-209 through yolk injection caused no significant

change in brain weights, yolk weights, liver weights, heart weights, or total body weight. The
tissue weight data were then transformed into a biological index value that expresses an organ
weight as a percentage of total body weight. Again a one-way ANOVA with follow up
Tukey’s test was run. No statistically significant differences were detected between the tissue
weight values or indices of the dosed and vehicle control injected embryos. However, the
presence o f edema and death in many of the embryos at the time of sampling precluded the
use of tissue weight data in the analysis.

D.2: Dose Verification
Qualitative and quantitative dose validation is an important step in toxicological
studies. The results of the dose verification indicated that the nominal doses were accurate
enough to be used in the survival analysis and calculation of the LD50. The confirmation of
the High Dose was the most consistent. The mean recovery was 91% with a standard
deviation of 6%. The concentration of the High Dose emulsion was 800 pg BDE-209 per ml
of emulsion. This High Dose emulsion was used in both trials three and four. In trial 3, 100
pi or 80 pg BDE-209 per egg of the High Dose emulsion was administered to the BDE-209
treatment group. In trial four, only 50 pi or 40 pg BDE-209 per egg of the High Dose
emulsion was administered to the High Dose treatment group. In the survival analysis, the
data from 5 treatments were used to create the CDF; the 80, 40, 20, 5 and the 0 pg BDE-209
per egg (vehicle treatment). Therefore, the confirmation of the High Dose at 91% recovery
supports the accuracy of the dosages administered to both the 80 pg BDE-209 per egg
treatment group and the 40 pg BDE-209 per egg treatment group.
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Impurities within the technical BDE-209 used to make the emulsions must also be
considered. In Figure R.l the contributions of the BDE-206 and -207 are illustrated
(determined from the Medium Dose Emulsion). When the concentrations of these two nonaBDE congeners are summed with the BDE-209 concentrations, the recoveries for the Medium
Dose Emulsion are improved. The mean recovery for the Medium Dose Emulsion,
accounting for the nona-BDEs, was 84.7%.
The possibility o f non-PBDE impurities must also be addressed. BDE-209 is known
to undergo photolytic debromination and furan formation (Hagberg et al. 2006, Kajiwara et al.
2008). Furans are highly toxic compounds. No fiirans were detected in the extracts of the
dosing solution. Careful screening of the dose extracts was made for the Octa-PBDF that
was identified in some of the dosed yolk samples. Again no furans were detected in any of
the dosing solutions. This is likely due to the fact that BDE-209 solutions and emulsions
were ALWAYS stored in amber glassware to prevent photolytic degradation that would
confound the results of this study.
Even with the nona-BDEs taken into account, the recoveries for the Low Dose
Emulsion were below 70%. While, this is less than ideal, it is not enough reason to abandon
the nominal concentrations for the survival analysis. The analysis of the Emulsion Vehicle
itself revealed no contamination of BDE-209. Therefore, accurate (80% or greater)
confirmation of four of five doses administered in this study validate the use of nominal
concentrations in the survival analysis.
The formulation of the emulsion vehicle required a highly concentrated BDE-209
spiking standard. BDE-209 is not very soluble in most solvents. Analytical standards for
BDE-209 are not available for over 50 pg/ml. A concentration of 4 mg/ml BDE-209 was
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desired to spike the emulsion formula. This standard was made by purchasing neat BDE-209
(Wellington Labs, Guelph, Ontario, Canada). The neat BDE-209 was dissolved in a solvent
mixture of diethyl ether and toluene (1:1 v/v). To accomplish this, a probe sonicator was used
for 30 minutes. The spiking solution showed 87% of the total PBDEs was BDE-209. The
Middle Dose extraction has only 76% of the total PBDEs as BDE-209 (See Figure D.2).
There are two possibilities that need to be addressed. First, did debromination of BDE-209
occur during the sonication and dissolution step? Second, did debromination of BDE-209
occur during the extraction step of the middle dose analysis?

Figure D.2: PBDE Percent Composition of the BDE-209 Spiking Solution and Middle
Dose Extraction
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The first question poses an interesting issue. We know that BDE-209 is photolytically
labile; particularly so, when dissolved in solvent. The sonication/dissolution step was done in
amber glassware. This reduces the likelihood of the photolysis pathway. The only other

mechanism would have to involve molecular excitement from the sonicator. While not
impossible, this is thought to be unlikely.
The second question poses the possibility that debromination occurred during the dose
extraction process. This is more likely. The emulsified dose was extracted in a separatory
funnel after dilution. The funnel was not made of amber glass. Therefore, attempts were
made to shield the contents from light. During the shaking and settling steps, the funnel was
wrapped in aluminum foil. Unfortunately, the foil had to removed for the collection steps, in
order to visualize the layers. This may have provided an opportunity for photolysis.

D.3: BDE-209 Egg Distribution and Biotransformation
D.3.1: Methodology
Chemical analysis of BDE-209 in biological tissues can be difficult due to its high
molecular weight, high boiling point and potential to thermally degrade in the GC when
subjected to high temperature. In a GC/MS, coincident biogenic compounds can distort
chromatography and interfere with signal generation. These issues were observed in the
course of analyses o f some yolk samples in this study. The yolk of a developing chicken
embryo acts as both a nutritional supply and waste collection compartment, containing lipids
for consumption and metabolic byproducts, respectively. The analytical procedure was
designed to remove water (freeze drier), extract lipophilic constituents (ASE) and remove
extraneous materials from the analytes (SEC and silica SPE steps). Certain tissues, especially
yolk, liver, and carcasses, contained greater amounts of extractable lipids. In effect, the high
lipid content of both the yolk and carcass samples limited the amount of sample that could be
analyzed at once, i.e. 1 and 1.5 g dry weight, respectively.
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The presence of co-extracted biogenic compounds in the samples appeared to interfere
with the BDE-209 signals in multiple spike recovery tests. Using the original extract
purification method (LaGuardia et al. 2006a) apparent 2- fold increases in BDE209 was
observed, for the yolk and carcass samples, respectively, data not shown. In addition,
biogenic materials co-extracted from these matrices also accumulated on the GC column and
impacted separation performance. For these reasons, further clean up of the sample extracts
was required.
Alternate cleanup methods focusing on the final SPE step were investigated. The
approach was to employ a weaker elution solvent regime to minimize carry-over of co
extracted biogenics. During the course of this work an interesting finding was made. BDE209 was observed to be the first of the PBDE congeners to elute off the silica gel columns
used. The initial expectation was that the less brominated congeners would elute earlier and
BDE-209 would be the last of the PBDEs removed from the column. The opposite trend was
observed. Grimvall and Ostman (1994) also observed this phenomenon. Bromine atoms are
larger than chlorine atoms. Bromines are halogens like chlorines, however their placement in
the periodic table makes them less electronegative than chlorines.

D.3.2: Tissue Distribution of BDE-209
Once an appropriate method of sample clean up was identified, the analysis of the
samples en mass could begin. The results indicated that BDE-209 was mobilized from the
yolk, into the heart, brain, liver, and remaining carcass of the developing chicken embryo.
These findings are consistent with those from Van Den Steen et al. (2008). What remains
unclear from the tissue distribution data is the true absorption rate of the compound into the
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embryo. The fact that 80% of the total administered dose was found in the yolk clouds the
issue. It is clear that some of the BDE-209 injected into the yolk was mobilized through the
embryonic vascular system. It is not clear how much of the dose traveled through the
embryo. The chicken yolk-sac acts as both a food source and a waste receptacle throughout
incubation. Therefore, there is no way to confirm if the BDE-209 detected in the yolk-sac
traveled through the developing embryo and was excreted back into the yolk-sac as waste, or
if it is simply the unabsorbed remaining dose.
In mammals, neurological toxicity at low BDE-209 concentrations has been reported.
Viberg et al have published multiple studies showing that neonatal exposure to BDE-209 may
impact spontaneous behavior and habitutation. Viberg et al (2003) revealed that BDE-209
can pass the blood brain barrier in neonatal mice. Viberg et al (2007) also showed that rats
exposed to BDE-209 during the neonatal brain growth spurt show altered responses to
nicotine in adulthood. Viberg et al (2008, 2009) later examined the impact of neonatal BDE209 exposure to neural protein concentrations in rats. The findings of these studies indicate
that in mammals BDE-209 enters the brain and alters protein concentrations in ways that can
cause permanent neurological changes if the exposure occurs during the brain growth spurt
(BGS).
A major objective of this study was to determine the tissue distribution of BDE-209
within the avian embryo. Previous work has indicated that BDE209 in rats does not distribute
strictly according to the concentration of lipid with tissues in rats (Huwe et al 2008). They
reported preferential accumulation of BDE209 in liver and muscle. BDE-209 was detected in
one of the composite pooled brain samples. This indicates that BDE-209 does pass the bloodbrain barrier in the chicken embryo. Therefore, the potential for neurological effects similar
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to those reported in mammals (Viberg et al., 2008) exists in birds. It is also noteworthy, that
while BDE-209 was detected in very low concentrations (<BQL) in the brains of the dosed
birds. The BDE-209 detected in the brains of the dosed embryos accounts for only 0.04% of
the total administered dose. The brain samples were all less than 1 gram. This led to a rather
high quantitation limit of 2000 ng/g lw.
BDE-209 was also detected (Below the Quantitation Limit or BQL) in the composite
dosed heart muscle samples. This is consistent with the idea that BDE-209 was mobilized
from the yolk compartment through the vascular system of the developing embryo. The
literature seems to suggest that BDE-209 is mobilized in the blood (Huwe et al. 2008) and is
relatively high in avian muscle tissue. Liang et al. (2008) identified BDE-209 as the dominant
PBDE congener in foraging chicken hens from an electronic waste recycling area in southern
China. Liang et al. (2008) showed peak BDE-209 levels in muscle tissue of 17,977 ng/g lipid
wt. The levels reported in the heart tissue were lower than skeletal muscle, with an average of
1135 ng/g lw. Like the brain samples, very little sample was available for analysis, only 0.1 g
per pool of four. Therefore, these samples were reduced in volume and pooled together to
lower the detection limits. Again, there was a trade off here between statistical power and
detection limit, the reason the samples were analyzed individually first. Since BDE-209 was
not detected, the detection limit must be lowered to confirm this finding. However, when
pooling tissues and concentrating extracts, one may also encounter additional matrix
interference issues in the GC/MS.
The fact that BDE-209 was detected in all of the dosed carcass samples indicated that
it spread from the yolk into the embryo during development. The most logical mechanism for
this movement was through the blood. Van den Steen et al. (2007) monitored BDE-209 in the
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blood of adult starlings. The muscle tissue BDE-209 concentrations were two-fold the liver
tissue BDE-209 concentrations in the Van den Steen study.
All of the liver samples from dosed eggs contained relatively high concentrations of
BDE-209. The average concentration of 3600 ng/g lw represents about 7% of the total 20,000
ng/egg dose. The presence of high levels of BDE-209 in the liver was anticipated. Many
researchers have reported BDE-209 concentrations in liver tissue of wild or free-ranging
birds. Jaspers et al. (2006) observed 68 ng/g lw of BDE-209 in the liver tissue of barn owls
from Belguim. Luo et al. (2009) reported a mean BDE-209 concentration of 18 ng/g lw in
liver tissue from chickens in South China. In a similar study, Liang et al. (2008) found 495
ng/g lw in the liver of chickens at an electronics recycling site in South China. Chen et al.
2007 detected the highest concentrations of BDE-209 in livers, of Chinese birds of prey, a
mean value of 12,200 ng/g lw..

D.2.3: Other PBDEs detected
The three possible nona-BDEs (BDE-206, 207 and 208) were detected in all of the
dosed yolk and liver samples. Nona-BDEs were not detected in any of the carcass, brain or
heart muscle samples. The sum of the average concentrations for each of the individual nonaBDEs in the dosed liver samples was 741 ng/g lw. If this is added to the average liver BDE209 concentration of 3600 ng/g lw the total would be 4340 ng/g lw. The average total lipid
weight for the pooled liver samples was 0.40g. This amounts to 1736 ng BDE-209 in the liver
compartment instead of 1440 ng. The change is relatively insignificant in calculating the
percentage of the total dose, the new value is 8.7% versus the old value of 7.
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The sum of the average concentrations for each of the individual nona-BDEs in the
dosed yolk samples was 1800 ng/g lw. If this is added to the average liver BDE-209
concentration of 9000 ng/g lw the total would be 10,800 ng/g lw. The average total lipid
weight for the pooled liver samples was 7g. This amounts to 75,000 ng BDE-209 in the yolk
compartment.
In viewing the yolk samples individually, some interesting patterns emerge. As all of
the samples represent a pool of four tissues, individual analysis can not be conducted. The
pool becomes the experimental unit and may mask some of the variation that occurred within
the individual embryos. Figure D.2 shows the BDE-209, -208, -207, and -206 trends in the
yolk samples. Sample YD7 clearly exhibited the lowest levels of BDE-209 and the highest
levels of all three nona-BDEs. This is the type of pattern one would expect to see if metabolic
debromination was occurring in some embryos.
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Figure D.3: Mean Deca- and Nona-BDE concentrations in pooled liver, yolk, and
carcass samples from BDE-209 dosed eggs
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In the yolk samples it is clear that BDE-206 is the dominant non-BDE congener. This
is not the case in the liver samples. In the liver samples BDE-207 is the dominant nona-BDE
congener. It is unclear if this is due to metabolic formation of BDE-207 in the liver. No octaor hepta-BDEs or lower (other than BDE-166) were detected in any of the samples. A
comparison of the congener profiles of the samples from this study and those of the available
Deca-BDE commercial formulations is required. Figure D.4 shows the congener profiles of
the two most common Deca-BDE products (LaGuardia et al., 2006).
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Figure D.4: Congener profiles of two commercial Deca-BDE formulations
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In both commercial Deca-BDE formulations presented in Figure D.4 BDE-206 is the
dominant nona-BDE congener. The Bromkal 82-BDE product contains trace amounts of
octa-BDEs (<0.5%). The Saytex 102E product does not contain octa-BDE impurities. No
octa-BDEs were detected in any of the samples from this study. If the octa-BDEs were
present then they were always BQL.
D.2.4: Other brominated compounds detected
The detection of an Octa-PBDF in three of the yolks samples raised some questions.
There are several possibilities to explain the presence of this compound therein. One
possibility is that an impurity existed within the BDE-209. Indeed, Hanari et al (2006)
reported octabromodibenzofuran to be a substantial impurity of the commercial decaBDE
product DE-83. It was the dominant brominated furan observed, present at up to 48 ng/g.
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Alternatively, the PBDF may have formed through photolytic breakdown of BDE-209
during the analytical process. However, except for the lipid determination and final solvent
volume reduction steps, the samples were always stored in amber glassware to prevent
photolytic degradation of BDE-209. The literature indicates that PBDFs may be created by
photolysis of BDE-209 (Hagberg et al. 2006; Kajiwara et al. 2008). Both of these studies
identified numerous PBDFs in light-xposed BDE-209 samples. For example, Hagberg et al.
(2006) identified 27 different PBDFs breakdown products. While they did not monitor the
hepta- and octa- brominated PBDFs, Kajiwara et al. (2008) did in an experiment investigating
the photolysis of BDE-209 in plastics. However, again multiple PBDF congeners were
reported. The majority of these were the lesser brominated tri through hexa- PBDFs. This
information leads this author to hypothesize that this single, fully-brominated PBDF was not
formed through photolytic degradation as more samples would have likely been affected and
additional PBDF congeners formed.
The third possibility for the occurrence of this furan was laboratory contamination.
This can not be completely ruled out, but it also seems unlikely. Contamination of only five
samples out of a total of 96 indicates that the contamination was not systematic in the
analytical method. Furthermore, this compound is not kept in the laboratory inventory and is
not used in commercial products. So, the contamination would have had to some from a light
exposed solution of BDE-209 or other source. Quality control measures should have
prevented this. Again, had the contamination come from a photolytically degraded BDE-209
solution, it is likely that other furans would also be present.
A fourth possibility is that this furan was formed inside the embryo. Formation of this
compound would require the loss of two bromines from the para- positions on each ring and
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the subsequent formation of the C-C bond between the two rings. The theorized mechanism
for debromination in birds is the reductive debromination by 5’-MA (deiodinase),
preferentially at the meta (5) position (Valverde et al. 1993). Therefore, the loss of two
bromines from the para- positions can not be explained by this specific mechanism. The
potential exists for an alternate mechanism within the embryo to explain this observation.
However, the details of that mechanism are not understood.
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CONCLUSION:

The findings of these studies indicate that BDE-209 is toxic to chicken embryos when
injected into the yolk, exhibiting an LD50 of 740 ng/g over a 20 day exposure via yolk
injection. This is roughly 6000 times less toxic than TCDD to embryonic chickens. The
distribution analysis of the five compartments (yolk, liver, brain, heart, and carcass) is
consistent with published literature indicating that BDE-209 is transported by the blood
throughout the embryo. No definitive evidence of metabolic debromination by chicken
embryos was seen. Both tissue extracts and the dosing emulsion exhibited low levels of nonaBDE congeners. Highest BDE-209 concentrations were in the yolk at the conclusion of the
study, day 20 (just prior to pipping). The yolk compartment acted as both a source (from the
initial injection) and a likely sink (recipient of waste products) for BDE-209 and contributed
to this result. A more complex distribution model (i.e. with more compartmentalization) is
recommended for future similar work. In addition, I would recommend that the embryos be
allowed to hatch, absorb all of their yolk and the BDE-209 in the yolk. Then sacrificed at 3-4
days o f age to determine how much of the administered dose actually ended up in tissues and
how much was excreted and /or metabolized. This author believes a microsomal assay similar
to that from Stapleton et al. (2006) could be used to address the question of metabolic
debromination of BDE-209 by avian embryos.
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Appendix A: Moisture Weight Loss throughout Egg Incubations

Figure A .l: Moisture Weight Loss for Trial 1
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Figure A.2: Moisture Weight Loss Trial 2
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Figure A.3: Moisture Weight Loss in Trial 3 Non-Injected Eggs
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Figure A.4: Moisture Weight Loss in Trial 3 Vehicle Injected Eggs
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Figure A.5: Moisture Weight Loss in Trial 3 BDE-209 Injected Eggs
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Appendix B: Conversion of Tissue Compartment Dry Weights to Wet Weights

Figure B.l : Dry Weight Versus Wet Weights of Pooled Brain Samples
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Figure B.2: Dry Weight vs. Wet Weight for Pooled Carcass Samples
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Figure B.3 Comparison of sample dry weights to wet weights.
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Figure B.4: Heart Muscle Samples Wet Weight vs. Dry Weight
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Figure B.5: Yolk Samples Wet Weight vs. Dry Weight
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Appendix C: Mass Balance on an Individual Sample Basis

Sample Pool 1

Sample LD1 was lost during sample processing. Therefore, the mean liver
concentration is used in these calculations. The data are presented in Table R.23. A total of
48,800 ng of BDE-209 is accounted for in the form of BDE-209. A total of 8200 ng of BDE209 can be accounted for in the form of the three Nona-BDEs. This leads to total detection of
roughly 71% of the total administered dose to Sample Pool 1.
Table C.l: Sample Pool 1
BDE209
(ng/g
dw)

Total BDE-209(ng) in
pooled T issue Sample

Total Sum Nona-BDEs
Sum Nona-BDE; (ng) in pooled tissu e
(ng/g dw)
sam ple

BD1

0

0

0

0

MD1

0

0

0

0

LD1

1800

1800

260

260

CD1
YD1

116
220

3000
44000

0
390

0
7900

SUM

48800

8160

SUM

Sample Pool 2
Table C.2: Sample Pool 2

BDE209
(ng/g
dw)
BD2
MD2
LD2
CD2
YD2

0
0
880
105
3500

SUM

Total BDE209(ng) in
pooled T issue
Sample
0
0
790
2900
60000

63690

Total Sum NonaBDEs (ng) in
pooled tissu e
sam ple

Sum NonaBDEs (ng/g
dw)
0
0
130
0
470

0
0
120
0
8000

8120

SUM
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Sample Pool 3
Table C.3: Sample Pool 3

BDE209
(ng/g
dw)
BD3
MD3
LD3
CD3
YD3

Total BDE-209(ng)
in pooled T issue
Sample

0
0
1000
110
3100

Sum NonaBDEs
(ng/g dw)

0
0
110
2940
68000

SUM

71050

0
0
230
0
660

SUM

Total Sum NonaBDEs (ng) in
pooled tissu e
sam ple
0
0
250
0
13600

13850

Sample Pool 4
Table C.4: Sample Pool 4

BDE209
(ng/g
dw)

Total BDE209(ng) in
pooled T issue
Sample

Total Sum NonaBDEs (ng) in
pooled tissu e
sam ple

Sum NonaBDEs (ng/g
dw)

BD4

0

0

0

0

MD4

0

0

0

0

LD4

1850

1850

370

370

CD4

80

2200

0

0

YD4

3900

74880

410

7900

SUM

78930

8270

SUM
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Sample Pool 5
Table A.5: Sample Pool 5

BDE209
(ng/g
dw)

Total BDE209(ng) in
pooled T issue
Sample

Total Sum NonaBDEs (ng) in pooled
tissu e sam ple

Sum NonaBDEs (ng/g
dw)

BD5

0

0

0

0

MD5

0

0

0

0

LD5

1170

1170

220

220

CD5

70

1780

0

0

3700

74400

370

7400

YD5

SUM

77350

7620

SUM

Sample Pool 6
Table C.6: Sample Pool 6

BDE209
(ng/g
dw)

Sum
NonaBDEs
(ng/g
dw)

Total BDE209(ng) in
pooled T issue
Sample

Total Sum NonaBDEs (ng) in
pooled tissu e
sam ple

BD6

0

0

0

0

MD6

0

0

0

0

LD6

2600

2340

39 0

351

CD6
YD6

140
4100

3800
70500

0
370

0
6400

76640

SUM

6751

SUM

Sample Pool 7
Table C.7: Sample Pool 7

BDE209
(ng/g
dw)

Total BDE-209(ng)
in pooled T issue
Sample

Sum NonaBDEs (ng/g
dw)

Total Sum NonaBDEs (ng) in
pooled tissu e
sam ple

BD7

0

0

0

0

MD7

0

0

0

0

LD7

1840

1660

430

390

CD7
YD7

97
4200

2400
80600

0
1400

0
26880

SUM

84660

SUM
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27270

Sample Pool 8
Table C.8: Sample Pool 8
BDE209
(ng/g
dw)

Total BDE209(ng) in
pooled Tissue
Sample

Sum
NonaBDEs
(ng/g dw)

Total Sum NonaBDEs (ng) in
pooled tissu e
sam ple

BD8

0

0

0

0

MD8

0

0

0

0

LD8

1900

1710

210

190

CD8
YD8

320
3860

8400
63700

0
380

0
6270

SUM

73810

6460

SUM
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